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CT   Computer tomography 
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PARP   Poly ADP ribose polymerase 
PCOS   Polycystic ovarian syndrome 
PD-1   Programmed death receptor-1 
PD-L1  Programmed death receptor ligand-1 
PET-CT  Positron emission tomography-computer tomography 
PI3K   Phosphinositide 3-kinases 
POLE   Polymerase epsilon 
PR   Progesterone receptor 
ProMisE  Proactive Molecular Risk Classifier for Endometrial Cancer 
PSA   Prostate specific antigen 
PTEN   Phosphatase and tensin homolog  
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SAM   Significance Analysis of Microarray 
TCGA  The Cancer Genome Atlas 
TGF-β  Transforming growth factor-β 
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Background: Endometrial cancer is the most common gynecological malignancy in 
the Western world. The disease occurs in the epithelial lining of the uterus, called the 
endometrium. Although prognosis is good and most of the patients are diagnosed at an 
early stage, 15-20 % of patients experience recurrence. An accurate risk-stratification 
is lacking and as incidence is increasing due to the increased prevalence of obesity and 
extended life-expectancy, biomarkers for improved risk-stratification are needed.   
Main objective: The main objective was to define biomarkers to better identify high-
risk patients from low-risk patients in order to individualize therapy and targeted 
treatment.  
Materials and methods: A prospectively and population-based series was collected 
and includes endometrial hyperplasias, primary tumors and metastases (Paper I-IV). 
Immunohistochemical staining was used for evaluation of HSF1, MSH6, PD-L1 and 
PD-1 (Paper I, III and IV). ELISA was performed for determination of plasma GDF-
15 (Paper II). RNA microarray data were used for evaluation of mRNA levels (Paper 
I, III and IV). 
Results: High expression of HSF1 associated with aggressive disease and poor survival 
in endometrial cancer. Protein level of HSF1 increased from primary tumors to 
metastasis. We found HSF1 to be an independent prognostic marker within ER-positive 
patients, a patient group with a presumed favourable prognosis. Gene expression 
analyses identified HSP90 inhibitors for targeted therapy (Paper I).  
High plasma levels of GDF-15 associated with aggressive disease characteristics and 
poor prognosis, also in low-risk patients. GDF-15 can indicate recurrence during 
follow-up and was an independent marker for recurrence. We validated the role of 
GDF-15 as an independent marker for lymph node metastasis (Paper II).  
PD-L1 and PD-1 are frequently expressed in endometrial cancer, 59% and 63%, 
respectively (Paper III). Expression was similar across MSS and MSI tumors. PD-L1 
and PD-1 have no impact on survival, nor when stratified for MSI. In corresponding 
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metastatic lesions, expression was discordant and intra-variable compared to primary 
tumors.  
High protein level of MSH6 identified aggressive endometrial cancer, also in low-risk 
patients (Paper IV). The prognostic value of MSH6 was validated both in curettage 
and hysterectomy specimen. MSH6 has independent prognostic impact preoperatively 
adjusted for age, histological risk-classification and hormone receptor status in the 
whole patient cohort. Also in a subgroup of patients with a putative low-risk disease, 
MSH6 demonstrated independent prognostic impact adjusted for age and hormone 
receptor status (Paper IV).  
Conclusion: High expression of HSF1, GDF-15 and MSH6 predicts aggressive disease 
and poor survival (Paper I, II and IV). GDF-15 is an independent predictor of 
recurrent disease and lymph node metastasis (Paper II). PD-L1 and PD-1 are 
frequently expressed and expression pattern is similar across MSS and MSI tumors. 
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1.  Introduction 
1.1 General introduction to endometrial cancer 
Cancer is a leading cause of death worldwide and constitutes an enormous burden on 
society in both developed and less developed countries. Ovarian, cervical, vulvar and 
endometrial cancer are the main gynecological cancers. Among these cancer types, 
endometrial cancer is the most common gynecological malignancy in industrialized 
countries (1). It arises from the epithelial lining of the uterus, called the endometrium 
(Figure 1). Obesity is the main risk factor and incidence rates are rising, due to the 
higher prevalence of obesity and the prolonged life expectancy (2, 3). The overall 
prognosis is good and about three quarters of patients are diagnosed at an early stage 
(4). However, accurate risk-stratification is lacking and about 15-20% of patients 
experience recurrence. Treatment options for women with advanced, recurrent and 
metastatic disease are sparse and little improvement has been made the last decades. 
The disease has been largely under-studied and the potential for improvement of risk-
stratification and therapy is substantial. In order to optimize and individualize 
treatment, there is a need for novel biomarkers to better define high-risk patients from 
low-risk patients (4). This thesis will focus on biomarkers that may aid in predicting 
prognosis and potentially guide therapy.  
 
Figure 1: Endometrial cancer occurs in the epithelial lining of the uterine cavity. 




Endometrial cancer is the 6th most common cancer among women worldwide and the 
most common gynecological malignancy in the Western world (5). The disease 
affected about 382 100 women worldwide in 2018 (5). In Norway there were 
approximately 750 new cases in 2017 (Figure 2) (6). The incidence has been steadily 
increasing over the past years, and the incidence is expected to further increase due to 
the prolonged life-expectancy and the increasing prevalence of obesity (4). Prediction 
models suggest between 1016-1257 new cases of endometrial cancer annually in 
Norway by 2025 (7). 
 
 
Figure 2: Incidence rates of uterine cancer in Norway by five-year period 1958-2017. 

















































Endometrial cancer is in general associated with a favorable survival. About 75 % of 
endometrial cancers are diagnosed at an early stage and the tumor is still confined to 
the uterine body (1). The overall prognosis is good with a 5-year relative survival of 
84%. For patients with localized disease survival rates are 95%, however, survival 
drops to 59% when the patient have regional spread to the serosa of the corpus uteri, 
and/or adnexa, vaginal and/or parametrial involvement or metastatic pelvic nodes,  and 
further drops to 40% if distant and metastatic spread have occurred (Figure 3) (6). 
 
Figure 3: Five-year relative survival in Norway by stage and period of diagnosis, 1978-
2017.  
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1.1.2 Risk factors  
Acquired risk factors 
Most endometrial cancers occur sporadic and the acquired risk factors are well known. 
Excessive estrogen production, obesity, physical inactivity, nulliparity, polycystic 
ovarian syndrome (PCOS), increasing age and history of breast cancer increase the risk 
of endometrial cancer (2, 8).  
In endometrioid adenocarcinomas, counting about 80% of all endometrial cancers, 
excessive estrogen production is the main risk factor (1). Increased exposure of 
estrogens to the endometrium may cause increased proliferation and subsequently 
endometrial hyperplasia, and increased risk of developing endometrial cancer (9). 
Obesity results in inflammation and alteration of adipokine signaling. Further, it leads 
to secondary changes related to insulin signaling and lipid dysregulation that may foster 
cancer development (10). Higher risk of endometrial cancer by increased body mass 
index (BMI) has been demonstrated and overweight and obesity have been estimated 
to account for about 40% of cases of endometrial cancer in Europe (8, 11, 12). Also, 
the risk of death from endometrial cancer increases with higher BMI with a relative 
risk (RR) of 2.53 in women with BMI 30 to 34.9 kg/m2 and a striking RR of 6.25 in 
women with BMI of at least 40 kg/m2 (13). Sedentary behavior has demonstrated up to 
66% increased risk of endometrial cancer (14). A potential beneficial effect of exercise 
and weight loss in postmenopausal and overweight women was demonstrated through 
decrease in free estradiol levels and increased levels of sex hormone-binding globulin 
(15). Further, physical activity, such as walking, showed a significant reduced risk of 
endometrial cancer (16, 17). Bariatric surgery demonstrated the effects of weight loss 
in reduction of circulating biomarkers for insulin resistance and inflammation (18). In 
addition, a reduction of endometrial Ki-67, phosphorylated-Serine473-AKT (pAKT), 
hormone receptors and restoration of glandular phosphatase and tensin homolog 
(PTEN) expression was displayed after surgery and subsequently weight loss (18).  
Women with PCOS have a 2.7-fold increased risk for developing endometrial cancer 
(19). PCOS is thought to increase the risk of endometrial cancer through chronic 
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anovulation and long-term exposure of estrogens to the endometrium unopposed by 
progesterone (20, 21).  
Hereditary risk factors 
Endometrial cancer most often occur spontaneously, however, Lynch syndrome and 
Cowden syndrome are both hereditary syndromes that are associated with an increased 
risk of endometrial cancer (22-25). Identifying patients with one of these predisposition 
syndromes is important in order to provide individualized assessments of cancer risk, 
as well as tailored screening and prevention strategies. 
Lynch syndrome, also known as Hereditary non-polyposis colorectal cancer syndrome 
(HNPCC), is an autosomal dominant inherited cancer susceptibility syndrome and 
responsible for most heritable endometrial cancers. About 2-6% of all cases of 
endometrial cancer are linked to Lynch syndrome (22, 23). The syndrome is associated 
with having a germline mutation in any of the DNA mismatch repair genes MSH2, 
MSH6, MLH1 or PMS2 resulting in reduced ability of mismatch repair and increased 
microsatellite instability (MSI) (26, 27). Individuals with Lynch syndrome have an 
increased lifetime risk of developing colorectal and endometrial cancer, and are often 
diagnosed at an early age. Lifetime risk of developing endometrial cancer is estimated 
to be about 42-60%, and the risk of developing endometrial cancer exceeds the risk of 
developing colorectal cancer in women (28-30). Identification of Lynch syndrome 
typically indicates tumor mismatch repair deficiency, which have implications for 
prognosis and possible treatment with targeted therapy.  
Cowden syndrome is an autosomal dominant syndrome associated with germline 
mutations in PTEN tumor suppressor gene (31). The syndrome is rare, affecting about 
1 in 200 000 individuals (32). Cowden syndrome is associated with multiple benign 
hamartomas and increased lifetime risk for malignancies such as breast, thyroid and 
endometrial cancer. Studies report up to 30% increased lifetime risk for endometrial 
cancer (24, 25). Cowden syndrome-associated endometrial cancer is associated with 
endometrioid subtype and younger age at time of diagnosis (24).  
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1.1.3  Clinical features and diagnosis 
Symptoms and diagnosis 
The main symptom in patients with endometrial cancer is postmenopausal bleeding or 
irregular bleeding, present in about 90% of cases (1, 4). This facilitates early diagnosis 
and about 75% of cases are diagnosed at an early stage when the tumor is still confined 
to the uterus (4). As most cases present with postmenopausal bleedings and are 
diagnosed at an early stage, the evidence to support screening for endometrial cancer 
has been poor in the general population (1, 33). Patients with more advanced disease 
at time of diagnosis may present with pelvic pain and abdominal distension (1). 
Postmenopausal bleeding is an unspecific symptom, as only 5-10% of all women 
presenting with postmenopausal bleeding have cancer, but risk of cancer-associated 
postmenopausal bleeding increases with age and presence of risk factors (2). When 
suspecting endometrial cancer, the doctor will perform transvaginal ultrasound (TVU) 
to visualize any suspect tumor in the endometrium. Histological verification is obtained 
by endometrial biopsy. Further preoperative staging is performed by imaging e.g. 
computed tomography (CT) or magnetic resonance imaging (MRI) to map the extent 
of tumor and create recurrence risk groups, in order to plan the surgical procedure and 
adjuvant therapy.  
Preoperative histology 
As a part of diagnostics and the preoperative assessment, the doctor will perform an 
endometrial biopsy by pipelle or curettage to determine histological grade and type. A 
key challenge in treatment of endometrial cancer is to preoperatively identify high-risk 
patients from low-risk patients. The preoperative assessment aims to classify patients 
into low-, intermediate- or high-risk groups regarding lymph node invasion and 
recurrence and to help guide surgical staging to determine whether lymph nodes should 
be removed and to what extent. Preoperative histology has proven to be discordant with 
final postoperative type and grading (34, 35). Studies have shown that up to 25% of 
cases with a preoperative grade 1 histology are upgraded on final pathology (34, 35). 
Subsequently, this may have consequences for the surgical approach, and whether to 
assign to lymphadenectomy or not. Although lymphadenectomy has not shown 
 21 
survival benefit, a complete surgical staging with lymphadenectomy has potential 
consequences for whether to assign the patient to adjuvant therapy, which may have 
implications on the patients’ prognosis (36).    
1.1.4  Preoperative imaging 
In addition to a preoperative biopsy for histological typing and grading, the patient will 
undergo preoperative imaging as part of the preoperative work-up to plan the surgical 
procedure. The most important factors to be determined are myometrial infiltration 
(MI), cervical stroma invasion and evaluation of metastatic spread, either to lymph 
nodes, or neighboring or distant organs. The type of modalities that are used varies 
extensively between countries and hospitals, and the modalities that are used in Norway 
are mentioned in brief below.  
TVU is a non-invasive method that is commonly available and affordable, and 
associated with a minimal discomfort for the patient. Ultrasound is helpful in deciding 
tumor location and determining tumor extent; MI and cervical stroma invasion. The 
method has, however, its limitations due to intervariable observations in between 
clinicians, especially among in-experienced doctors, and in the case of obese patients 
and limited possibility for evaluation of any retroperitoneal disease spread (37-40). 
CT with intravenous contrast is widely available and less expensive than MRI. CT has 
a clear advantage when determining distant tumor spread and lymph node metastases 
in the pelvis, abdominal cavity and thorax. However, due to the little contrast difference 
between the tumor and myometrium, CT is not sensitive nor specific enough to assess 
the depth of myometrial infiltration or cervical stroma invasion (37, 40).  
Pelvic MRI is a highly valuable imaging method for detection of deep myometrial 
invasion, cervical stroma invasion and metastatic lymph nodes. Although MRI is 
considered the best imaging method for preoperative staging in endometrial cancer, the 
diagnostic accuracy of MRI is reported to be variable (40).  
Fluorodeoxyglucose (18F-FDG) positron emission tomography-computer tomography 
(PET-CT) combines two imaging techniques and visualizes both morphologic and 
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metabolic tumor characteristics. The tracer 18F-FDG visualizes glucose metabolism, 
which is often increased in tumor cells (41). Reportedly, 18FDG PET-CT outperforms 
TVU and MRI in detecting lymph node metastases and distant spread, but is not suited 
for assessing depth of MI and cervical stroma invasion due to limitations of spatial 
resolution (40). 
Histopathology 
The final postoperative pathology report as well as the surgical staging, guide the 
clinician when assigning the patient for adjuvant treatment. Regardless of The 
International Federation of Gynecology and Obstetrics (FIGO) stage, endometrial 
cancers are classified according to their histological appearances, which is currently 
gold standard for patient risk-stratification. Endometrioid endometrial cancers are the 
most frequent histological type comprising about 80% of endometrial cancers. 
Endometrioid cancers are often estrogen-dependant and may be preceded by 
endometrial hyperplasia (9). Endometrioid carcinomas are typically composed of 
tubular glands lined by stratified or pseudostratified columnar cells with rounded nuclei 
and variably prominent nucleoli, and a varying degree of differentiation (2, 42). The 
non-endometrioid cancers are the most aggressive and constitute about 15-20% and 
serous and clear cell tumors are the most common types. Serous tumors presenting with 
a papillary growth pattern with highly pleomorphic tumor cells in which the tumor has 
frequent mitoses and necrosis, and clear cell tumors with a noticeable amount of clear 
cytoplasm (43, 44). The mixed tumors, carcinomas composed of more than one 
histological type with at least 10% of each component, are known to be challenging to 
properly classify for further treatment (45). 
Grading of endometrial cancer is based on the amount of solid growth of the glandular 
component, and is of prognostic importance (46). However, non-endometrioid tumors 
are classified as high grade by definition, thus grade has no relevance in prognostic 
stratifications for this cancer type (2, 47). Endometrioid tumors are classified as 
follows.  
Grade 1: well-preserved glandular pattern and less than 5% solid growth.  
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Grade 2: less well-defined glandular pattern and less than 50% of solid growth.  
Grade 3: hardly recognizable glands and more than 50% of solid growth.  
However, a major challenge in histopathological classification of endometrial cancer 
is tumor heterogeneity; small populations of cells with a different character within the 
same tumor that would have impact on diagnosis and treatment. In addition, inter-
observer variability in distinguishing between high-grade endometrioid carcinomas 
and non-endometrioid carcinomas is significant. In order to improve risk-stratification 
and guide treatment, and to add value to standard histopathological stratification, 
molecular markers are needed to reduce inter-observer-variability and to better identify 















FIGO staging  
Patients are surgically staged according to the FIGO staging system (Table 1) (48). The 
FIGO staging system was first introduced in 1988 (49) and revised in 2009 (48). 
Increasing FIGO stage implies increasing risk of recurrence and poorer prognosis, it is 
the strongest prognostic marker in endometrial cancer (47). In FIGO stage I and II, 5-
year survival rates range from 74-91%. In FIGO stage III and IV, 5-year survival rates 
range from 57-66% and 20-26%, respectively (1, 2).  
Table 1. FIGO staging system for endometrial cancer according to 2009 criteria.  
Stage Description (48) 
I Tumor confined to the corpus uteri 
   IA Myometrial invasion <50% 
   IB Myometrial invasion >50% 
II Tumor invades the cervical stroma, but does not extend beyond the 
uterus  
III Local/and or regional tumor spread 
   IIIA Tumor invades the serosa of the corpus uteri, and/or adnexa 
   IIIB Vaginal and/or parametrial involvement 
   IIIC1 Metastases to pelvic nodes 
   IIIC2 Metastases to para-aortic lymph nodes with or without positive 
pelvic lymph nodes 
   IVA Tumour invasion of the bladder and/or bowel mucosa 
   IVB Distant metastases including intra-abdominal metastases and/or 








The primary treatment of endometrial cancer is surgery and the cornerstone of 
treatment is hysterectomy with bilateral salpingo-oophorectomy with or without 
lymphadenectomy. In recent years, minimally invasive techniques such as laparoscopy 
(keyhole surgery) or robot-assisted surgery in low-stage disease have been increasingly 
used, reducing hospital stay and postoperative complications as opposed to laparotomy 
(open surgery) (50-52). For most patients simple hysterectomy is sufficient, but for 
patients with cervical stromal invasion radical hysterectomy is performed. 
Omentectomy is only performed in patients with high-risk histology; clear cell and 
serous (53). 
 
The extent of lymphadenectomy varies worldwide and its role in the management of 
endometrial cancer is controversial. Lymphadenectomy is necessary for a complete 
surgical staging. However, no benefit in survival has been reported (54-56), and 
adverse effects such as lymphedema and lymphocele are frequently described (36, 56). 
Traditionally, patients with a putative intermediate and high-risk disease are commonly 
assigned to lymphadenectomy (53). 
 
Sentinel lymph node mapping, a novel surgical technique replacing lymphadenectomy 
is becoming appreciated in many countries, as this may spare the patient from 
undergoing complete lymphadenectomy. The technique involves selective and limited 
removal of tumor-specific or organ-specific lymph nodes that are identified after 
injection of tracer dye into, or in proximity to, the primary tumor (57). Sentinel lymph 
node biopsy has proven equivalent to lymphadenectomy in staging of endometrial 
cancer and can potentially spare the patient from the unwanted side effects of 
lymphadenectomy, and still obtain complete surgical staging and reduce morbidity (58-
60). However, the support in literature is still limited and the technique is not yet 
implemented in most countries (36, 61). 
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Adjuvant therapy 
Adjuvant therapy may be beneficial to patients at high-risk of recurrence in order to 
reduce their risk of relapse. Combined chemotherapy with carboplatin and paclitaxel 
is the current standard first-line regimen, consisting of 6 cycles of 3-weekly paclitaxel 
and carboplatin and is administered to patients with high-risk of recurrence (62) 
(Table 2). In FIGO stage I this signifies that only grade 3 endometrioid cancers with 
MI ≥50 %, and all non-endometrioid cancers independent of MI are offered adjuvant 
chemotherapy, in addition to FIGO stage II-IV (33, 53). National guidelines in 
Norway are based on the ESMO/ESGO guidelines (63).  
Table 2. Risk of cancer relapse in patients with FIGO stage 1 (53). 
Low-risk Stage 1A grade 1 and 2 endometrioid subtype 
Intermediate risk Stage 1A grade 3 endometrioid subtype                                            
Stage 1B grade 1 and 2 endometrioid subtype       




A few trials have investigated the efficacy of chemotherapy. The evidence of benefit 
from adjuvant chemotherapy exists for patients with positive lymph-nodes, and the 
retrospective data is weak for the efficacy of chemotherapy in early-stage clear cell 
cancer (64). The Gynecologic Oncology Group 122 trial demonstrated improved 
progression-free survival and overall survival of doxorubicin and cisplatin versus 
whole abdomen irradiation in stage III and IV disease (65). However, an Italian trial 
and the Japanese Gynecologic Oncology Group trial did not demonstrate any survival 
benefit with chemotherapy compared to pelvic radiation (66, 67). These trials included 
mostly early-stage and low-grade disease, yet the difference in survival rates is not 
clear. A Cochrane review summarized a reduced risk of recurrence by adjuvant 
chemotherapy (68). Overall, endometrial cancer is considered a chemotherapy-
sensitive tumor and taxanes, anthracyclines and platinum agents are generally active in 
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chemotherapy-naïve patients. However, response to second-line chemotherapy has 
been poor and only taxans have proven response rates of 20% (69). 
Radiotherapy  
Radiotherapy can be delivered vaginally as brachytherapy or externally to the pelvis. 
Adjuvant radiotherapy as treatment for early-stage disease has been widely debated as 
studies have shown to improve local control, however, no proven effect on survival 
(70-73). There is ample evidence in literature supporting a reduced locoregional 
recurrence rate from 12-20% if no additional treatment is provided, to 3-5% after 
adjuvant radiotherapy in high-risk patients (70-73). However, most studies agree that 
radiotherapy to early-stage endometrial cancer does not convey a survival benefit (70-
73). Side effects after radiotherapy include chronic diarrhea, fecal leakage and reduced 
sexual functioning that can be debilitating and severely affect quality of life (74). In 
Norway, routine adjuvant radiotherapy in FIGO stage 1 and 2 patients was no longer 
offered after 2008 due to lacking evidence of survival benefit. The argument for this is 
that the majority of locoregional recurrences, if they occur, can be treated by 
therapeutic dosages of radiation, surgery and/or chemotherapy. In this way, 
unnecessary and long-term side effects can be avoided in most patients, preserving high 
quality of life, while still retaining high survival rates (75, 76).  
Chemoradiation, combining chemotherapy and radiotherapy has not shown survival 
benefit (64). A recent study, the PORTEC-3 trial did show significantly improved 5-
year recurrence-free and disease-specific survival with chemoradiotherapy compared 
to external-beam radiotherapy alone (77). However, no improvement in overall 
survival was demonstrated (77).  
 
Hormonal therapy  
Hormonal therapy is not recommended as adjuvant therapy, but may be considered in 
the metastatic setting, especially for tumors of low-grade endometrioid histology with 
a long time to recurrence (64). However, the response rates are modest and hormone 
receptor status is not always taken into consideration when assigning the patient to 
hormone treatment (78). Although response to hormonal therapy is more common 
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among patients with intact estrogen receptor (ER) and progesterone receptor (PR) 
expression, response rates and hormone receptor expression have proven discordant in 
prediction of response to hormonal therapy (79). 
Conservative treatment 
Conservative treatment may be of interest among patients with early stage endometrial 
cancer, that is stage 1A endometrioid grade 1 or 2, or endometrial hyperplasias. 
Especially among women of young age who want to preserve their fertility, or among 
women with comorbidity who are at high-risk of surgical complications. Oral progestin 
therapy with medroxyprogesterone or megesterol acetate has previously been the 
option, however, disease progression occurs in some cases and new therapeutic 
strategies and biomarkers to better select patients for treatment are needed (80).  
 
Intrauterine devices (IUD) releasing progesterone have shown success in converting 
endometrial hyperplasias to normal epithelium, both among young women wanting to 
preserve their fertility, and among older women who are not suited for surgical 
treatment (81). In women with stage 1A endometrioid grade 1 and 2 cancers oral 
progestins such as megestrol acetate or IUDs have shown regression of disease (82).  
 
The link between endometrial cancer and metabolic syndrome has made metformin 
interesting as treatment or adjunctive treatment for early endometrial cancer. 
Metformin has shown results in treating endometrial hyperplasia, especially among 
patients with PCOS and early stage endometrial cancer with reduction in tumor 
markers such as Ki-67, pAKT and ER (80, 83).  
 
When choosing conservative treatment, the patient should be informed of the risk of 
an inadequately staged/treated disease, an inherited genetic cancer risk and the 




Targeted therapy  
Targeted therapy, a treatment modality that is directed against a specific molecular 
target identified in the patients’ cancer or tumor microenvironment, is the cornerstone 
of precision medicine (84). One well-known example of targeted therapy is anti-HER2 
(trastuzumab) which has demonstrated good response rates in HER2-positive breast 
cancer patients (85). To date, no targeted therapies are established in clinical use for 
endometrial cancer patients. The lack of predictive markers to select patients for 
treatment has limited the potential of targeted therapies. Previously, temsirolimus 
(mTOR-inhibitor), trastuzumab and bevacizumab (VEGF-A-inhibitor) have been 
investigated; however, the response rates have been modest (86-88). Targeting 
aberrations of the phosphinositide 3-kinases (PI3K) pathway have also yielded modest 
results in clinical trials, however combined poly ADP ribose polymerase (PARP) and 
PI3K inhibitors in mouse models have shown synergistic effects (9). 
 
The identification of the four molecular subtypes in endometrial cancer by TCGA 
contributed to a shift of paradigm and gave momentum to further research for targeted 
therapy in endometrial cancer (89). Four distinct molecular subtypes were identified, 
each with distinct impact on survival. One of the molecular subtypes, MSI has emerged 
as a promising predictive biomarker for response to immunotherapy in solid tumors, 
due to the increased number of neo-antigens (90-92). Treatment with immune 
checkpoint inhibitors has become an appreciated treatment with promising response 
rates in the recurrent and metastatic setting in solid MSI-high tumors (93-95). Results 
have demonstrated less toxicity than chemotherapeutic regimens and a potential for 
durable response (93-95). As U.S. Drug and Food Administration (FDA) granted 
approval to pembrolizumab (PD-1-inhibitor) for treatment of advanced and recurrent 
MSI-high endometrial cancer, treatment with immune checkpoint inhibitors has 
become an option also for endometrial cancer patients (96). The KEYNOTE-028 study 
with treatment of pembrolizumab to PD-L1 positive, advanced MSI-high endometrial 
cancer has demonstrated promising results (97). A recent phase II study with avelumab 
(PD-L1-inhibitor) demonstrated promising results in MSI-high patients regardless of 
PD-L1 expression, but demonstrated no efficacy in MSS endometrial cancers (98).  
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However, treatment with immune checkpoint inhibitors may not be exclusively for 
patients with MSI-tumors. Several recent clinical trials indicate that patients with 
microsatellite stable (MSS) tumors may benefit from immune checkpoint inhibitors in 
combination with a second drug. In a trial based on biomarker unselected, advanced 
endometrial cancer patients, an objective response to combination therapy with 
pembrolizumab and lenvatinib (a multikinase inhibitor of VEGFR1, VEGFR2, 
VEGFR3) was recorded in 16 out of 45 patients with MSS-tumors, compared to two 
out of four patients with MSI-tumors (99). Recently, FDA approval was granted to 
lenvatinib in combination with pembrolizumab, for the treatment of patients with 
advanced endometrial cancer regardless of MSI, who have disease progression 
following prior systemic therapy and are not candidates for curative surgery or 
radiation. Promising results by combination therapy with PD-1 blockade and cytotoxic 
T-lymphocyte–associated protein-4 (CTLA-4) to MSS tumors have also been 














1.2 Tumor biology  
1.2.1 General tumor biology 
The human genome gives rise to hundreds of cell types with multiple functions. Cancer 
is by definition uncontrolled division of abnormal cells in any part of the body. For 
normal cells to evolve progressively to an abnormal and neoplastic state they acquire 
several capabilities in order for the cell to become malignant.  
Hanahan and Weinberg summarized several decades of intense cancer research in the 
two “Hallmarks of cancer” papers, further contributing to the understanding of cancer 
biology (101, 102). The hallmarks include sustaining proliferative signalling which is 
the most fundamental trait of cancer cells. By evading growth suppressors, tumor cells 
successfully circumvent powerful programs which negatively regulate cell 
proliferation. Activating invasion and metastasis for tumor cells to progress to higher 
pathological grades of malignancy. Enabling replicative immortality, which is in 
marked contrast to normal cells that have a limited number of growth-and-division 
cycles. Inducing angiogenesis by neovascularization to provide oxygen and nutrients. 
Resisting cell death in which apoptosis is attenuated in tumor cells and they succeed in 
becoming high-grade malignant. Two more emerging hallmarks have emerged, 
including avoiding immune destruction in which the immune system plays a role of 
resisting or eradicating formation and progression of early-stage neoplasias or late-
stage tumors and deregulating cellular energetics in which tumor cells upregulate 
glycolysis. Two enabling characteristics have also emerged, tumor-promoting 
inflammation, which is driven by cells of the immune system and serve as promoters 
of tumor progression and genome instability and mutation, which is responsible for 
random mutations and chromosomal rearrangements (101, 102).  
In recent years focus has been on detecting genomic alterations in the tumor. For 
precision oncology, it is crucial to identify molecular cancer drivers. A recent study 
identified 299 cancer drivers in a pan-cancer study comprising 33 cancer types, among 
the most frequent in endometrial cancer was tp53, PTEN, PIK3CA and MAP3K1 
(103).  
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1.2.2 Endometrial tumor biology 
Signalling pathways relevant for endometrial cancer and this project especially is 
discussed in brief in the paragraphs below.  
The heat shock response  
The heat shock response plays a central role in promoting survival and increased 
proliferation (104, 105). The heat shock response is the most conserved cellular 
protective mechanism and responsible for cellular homeostasis, by combatting the 
negative effects caused by stressors such as increased temperature, oxidative stress and 
inflammation (106). The transcriptional activator, heat shock factor 1 (HSF1), mediates 
the regulation of the heat shock gene transcription (107). HSF1 triggers massive 
transcription of genes, such as heat shock protein 90 (HSP90) and heat shock protein 
70 (HSP70), which facilitate normal protein folding and protect the proteome from 
misfolding and aggregation that could cause lethal damage. The role of HSF1 in cell 
survival has been linked to carcinogenesis, and the role of HSF1 to modulate 
oncogenesis was demonstrated in HSF1 knockout-mice, which had reduced 
susceptibility to tumor formation (108). Also, elevated levels of HSF1, heat shock 
protein 60 (HSP60) and HSP90 in aggressive prostate carcinoma cell lines have been 
demonstrated (109). Increasing evidence supports that HSF1 plays a crucial role in 
tumor formation, but the exact role is not fully understood (106). However, HSF1 in 
cell cultures demonstrated to support malignant transformation by increased 
proliferation, survival, protein synthesis, and glucose metabolism (105, 108).  
The Transforming Growth Factor (TGF)-β signalling pathway  
The TGF-β superfamily has a role in inflammatory and apoptotic pathways in injured 
tissues and during disease processes. The TGF-β pathway has been found to be 
redirected away from suppressing cell proliferation and instead become a tumor 
promoter (101). Growth factor differentiation factor-15 (GDF-15), also called 
macrophage inhibitory cytokine-1 (MIC-1), is a part of the TGF-β superfamily. It was 
first identified in activated macrophages (110). GDF-15/MIC-1 is involved in tumor 
pathogenesis and is associated with cell cycle arrest and apoptosis (111). Expression 
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of GDF-15/MIC-1 is mediated by p53 and studies have shown that measurement of 
circulating tumor-derived MIC-1 is a good in vivo indicator of p53 pathway activation 
(112).  
Immunosurveillance and checkpoint inhibitors  
The role of the immune system in tumor formation has been an unresolved issue and 
widely debated. However, in recent years, research has increasingly supported that the 
immune system can indeed prevent tumor formation. The theory of cancer 
immunosurveillance proposes that cells and tissues are monitored by an ever-alert 
immune system, which is responsible for recognizing and inactivating potentially 
dangerous mutant cells that can lead to tumor formation (101, 113). The impact of 
intratumoral lymphocyte infiltrates on clinical outcome have been demonstrated in 
several solid cancers, such as ovarian and colorectal, in which tumors with heavily 
infiltrated cytotoxic T-cells and natural killer cells have a better prognosis than patients 
that lack the abundance of these cells (114). In endometrial cancer, the presence of 
tumor infiltrating lymphocytes (TILs), specifically the presence of CD8+ T-
lymphocytes was demonstrated to be an independent predictor of improved overall 
survival, also in the subgroup of type II endometrial cancer patients (115). 
Consequently, immunotherapy has made its step into cancer care by treatment with 
immune checkpoint inhibitors, which have emerged as a major treatment modality in 
oncology and precision medicine. Potential targets for immune checkpoint inhibitors 
are e.g. PD-L1 and PD-1. PD-L1 is expressed on tumor cells and binds to the receptor 
PD-1 on cytotoxic T-cells. This binding causes suppression of the T-cell, as a negative 
feedback system that represses the immune system, and is a strategy for tumor cells to 
escape from the anti-tumor activity of T-cells (96). Antibodies to PD-1 or PD-L1 block 
the binding of PD-L1 on tumor cells to PD-1 receptors on T-cells, and allow the T-cells 





Figure 4: The PD-L1/PD-1 pathway. The figure shows how antibodies to PD-L1 and 
PD-1 block the PD-L1/PD-1 pathway and activates the T-cell in order to fight tumor 
cells.  
Figure is reprinted with permission from Cancers (116). 
The two types of endometrial cancer  
Traditionally, endometrial cancers have been divided into type I and type II (117, 118). 
Type I tumors are associated with obesity, metabolic syndrome and tumors are highly 
estrogen-dependent with a positive ER and PR status. Approximately 80% of the 
tumors are low grade (grade 1 and 2) while 20% are high grade (grade 3) (118). Type 
II tumors on the other hand, are not associated with metabolic syndrome, are less 
estrogen-dependent and comprise mostly serous tumors. Type II tumors are associated 
with aggressive clinical features such as deep MI and lymph-node metastasis, and thus 
have a poorer prognosis as opposed to type I tumors (118).  
The Cancer Genome Atlas project 
The Cancer Genome Atlas project is a joint effort between the National Cancer Institute 
and the National Human Genome Research Institute and began in 2006. The cancer 
genomics program has molecularly characterized over 20 000 primary cancers from 33 
cancer types with matched normal samples. In endometrial cancer, TCGA identified 
four molecular subgroups by performing integrated genomic, transcriptomic, and 
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proteomic characterization of 373 endometrial cancers (89). The four molecular 
subgroups were ultramutated polymerase epsilon (POLE), hypermutated MSI, copy 
number abnormalities-low and copy number abnormalities-high (Table 3). The TCGA 
publication has led to a shift of paradigm in endometrial cancer research, gaining more 
insight to the molecular landscape of endometrial cancer and slowly leaving behind the 
more traditional way of stratifying endometrial cancers into type I and II. There has 
been an increasing interest in integration of molecular markers and it has gained 
momentum to further research on the molecular level and targeted therapy especially.  
Table 3: TCGA classification of endometrial cancers 
Subgroup Selected characteristics (89):  
POLE ultramutated Very high number of mutations 
 Favorable PFS 
 Frequent mutations in PTEN, PIK3CA and KRAS 
MSI High number of mutations 
 Frequent MLH1 promoter hypermethylation 
 Low number of SCNAs 
 Few mutations in TP53 
Copy number high High number of SCNAs 
 Frequent TP53 mutations 
 Low degree of MSI 
 Poor PFS 
Copy number low Low mutation rate 
 Microsatellite stable 
POLE: polymerase PFS: progression-free survival. MSI: microsatellite instable SCNA: 
somatic copy number  
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A classification tool for clinical use  
A more pragmatic and less expensive classification tool of the four molecular 
subgroups by identification of surrogate markers has been proposed by the ProMisE 
(Proactive Molecular Risk Classifier for Endometrial Cancer) and TransPORTEC 
(Postoperative Radiation Therapy for Endometrial Carcinoma) initiatives (119, 120). 
TCGA data were conducted mainly on low-risk endometrial cancers and serous 
cancers, however clear cell cancers were lacking. The TransPORTEC has validated a 
simple molecular classification on high-risk endometrial cancer, resulting in four 
distinct molecular subgroups “POLE mutated”, “microsatellite unstable”, “TP53 
mutated” (surrogate marker for copy number-high) and “no specific molecular profile” 
(120, 121). ProMisE has defined “microsatellite unstable”, “POLE mutated”, “p53 wild 
type” and “p53 abnormal” (119, 122-124). Central in the defining of MSI by 
immunohistochemistry is the two mismatch-repair proteins MSH6 and PMS2. Lack of 
nuclear expression of either two proteins depicts microsatellite instability (119, 124), 
and the protocol has been applied in Paper III and IV. The application of more 
clinically applicable methods on formalin-fixed paraffin-embedded (FFPE) samples, 
using sequenzing and immunohistochemistry, serves as a potential routine clinical 









1.3 Biomarkers in endometrial cancer  
In endometrial cancer, prognostic markers are needed in order to better differentiate 
high-risk patients from low-risk patients (4). In order to improve clinical decision 
making and treatment strategies, predictive markers for response to therapy are highly 
needed (127). In spite of rigorous research the last years, few biomarkers have reached 
clinical practice (4).  
The Biomarkers Definitions Working Group has defined a biomarker as “A 
characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes, patho-genic processes, or pharmacologic responses to a 
therapeutic intervention”(128). Biomarkers can be measured in serum, plasma or urine, 
but more invasive techniques requiring tumor tissue, such as immunohistochemistry 
and DNA/RNA analyses are widely used (129). Anything that is quantifiable in a 
patient may potentially serve as a biomarker. For a biomarker to be of clinical interest 
it must add information to what is already known from established clinicopathological 
variables or predictors. Figure 5 illustrates the areas in the diagnostic work-up where a 
biomarker could be helpful in patient care.  
Biomarkers are in general categorized in two groups 1) Prognostic markers as tools for 
diagnosis, disease staging or indicator of disease outcome. 2) Predictive markers 





Figure 5: Examples of areas in the diagnostic work-up where a biomarker could be 
helpful in patient care.    
Detect cancers at 
a curable stage, 
before symptoms 
develop 













Early detection/screening Diagnosis Prognosis/monitoring Treatment selection 
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1.3.1 Prognostic biomarkers 
Prognostic markers provide information about the patients’ prognosis, regardless of 
therapy (129). To improve risk-stratification and tailor therapy, prognostic biomarkers 
are crucial in treatment of endometrial cancer. Prognostic biomarkers are in clinical 
use for several cancer types, such as prostate specific antigen (PSA) in prostate cancer 
(130), cancer antigen 125 (CA125) in ovarian cancer (131) and serum-derived 
carcinoembryonic antigen (CEA) in colon cancer (132). Established prognostic 
markers in endometrial cancer are all of clinicopathological origin and constitute e.g. 
FIGO stage, lymphovascular space invasion, histological grade and type (4). Although 
molecular biomarkers with prognostic impact are identified in endometrial cancer, 
none of them have reached clinical practice yet.  
Aneuploidy, overexpression of p53 and k-ras (KRAS) amplification have 
independently been associated with poor survival in endometrial cancer (133-135). L1 
cell adhesion molecule (L1CAM) protein expression has been proposed as a strong 
prognostic biomarker and predictor of lymph node metastases (136-138). The presence 
of TILs, specifically the presence of CD8+ T-lymphocytes were demonstrated to be an 
independent predictor of improved overall survival, also in type II endometrial cancer 
patients (115).  
However, a small step into clinical implementation is the identification of loss of both 
ER and PR in prediction of lymph node metastasis and poor outcome (139), which has 
led to The Molecular Markers in Treatment of Endometrial Cancer study 2 
(MoMaTEC2, NCT02543710). The trial is a phase IV implementation trial for 
optimized stratification of surgical treatment. Low-risk patients (endometrioid tumors 
grade 1 or 2, or grade 3 with <50% MI, with no sign of extrauterine disease) with 
positive hormone receptor status for both ER and PR will omit lymphadenectomy. 




1.3.2  Predictive biomarkers  
Predictive markers give information about the anticipated effect of a certain therapeutic 
intervention (129). Predictive markers are crucial in order to assign patients for targeted 
treatment. In several cancer types, predictive markers and treatment with targeted 
therapy have made progress the recent years, such as BRAF-inhibitors in treatment for 
metastatic malignant melanomas (140), and HER2-inhibitors in breast cancer (85). So 
far, in endometrial cancer, few predictive markers have emerged and consequently 
treatment with targeted therapy is limited. 
In endometrial cancer, ER and PR have been suggested to predict improved response 
to hormonal treatment (78, 141), and high expression of Stathmin has demonstrated to 
predict poor response to paclitaxel (142). 
MSI has emerged as a predictive marker for response to immunotherapy in solid 
tumors, and is an emerging marker for response to immunotherapy in endometrial 
cancer as well (90-92, 143). After FDA approved pembrolizumab (PD-1-inhibitor) for 
treatment of MSI-high recurrent and metastatic endometrial cancer, treatment with 
immune checkpoint inhibitors have become an option also for endometrial cancer 
patients (96). Programmed death receptor 1 (PD-1) and programmed death receptor 
ligand 1 (PD-L1) are established predictive markers and targets for treatment with 
immune checkpoint inhibitors in solid tumors (90, 143). The KEYNOTE-028 study 
with pembrolizumab to PD-L1 positive, advanced MSI-high endometrial cancer has 
demonstrated promising results (97). Targeted therapy with immune checkpoint 









2. Aims of the study 
2.1.1 Background and general aims  
An increasing number of patients are being diagnosed with endometrial cancer, and 
due to the prolonged life-expectancy and the increasing prevalence of obesity the 
numbers are expected to further increase. The overall prognosis is good, however 15-
20 % of patients experience recurrence. The survival rates for recurrent, metastatic and 
advanced disease are poor and little improvement has been made the last decades. Thus, 
it is urgent to find biomarkers that better select high-risk patients from low-risk patients 
to tailor therapy and develop targeted treatment. The overall aim of this study was to 
define biomarkers that better predict prognosis and guide therapy.  
2.1.2 Specific aims 
Paper I: Evaluate the prognostic impact of HSF1 in endometrial cancer. Also, we 
aimed to investigate the transcriptional alterations related to HSF1 protein level by 
microarray analysis.  
Paper II: Identify GDF-15 as a marker for recurrent disease. Additionally, we aimed 
to validate GDF-15 as a prognostic marker for aggressive disease and as an independent 
marker for lymph node metastases.  
Paper III: We aimed to determine the expression patterns of PD-L1 and PD-1 in both 
primary tumors and corresponding metastatic lesions, stratified for microsatellite 
instable and microsatellite stable cancers.  
Paper IV: The aim of this study was to determine the prognostic value of MSH6 both 






















3. Materials and methodological considerations 
3.1.1 Patient series 
All samples included in the study were retrieved from the Bergen Biobank for 
Gynecological Cancer (REK number 2014/1907). Patients included in the study are 
diagnosed and treated for endometrial cancer at Haukeland University Hospital, 
Bergen, Norway. All patients are prospectively included from 2001 to 2015. Haukeland 
University Hospital is a referral hospital for Hordaland County and covers 
approximately 10 % of the population. The cohort is considered population-based as 
incidence rates, patient- and disease characteristics are representative of the entire 
Norwegian population (6).  
All patients gave written informed consent prior to study inclusion. Patients were 
treated according to current national guidelines. Blood samples and urinary samples 
were collected for research purpose preoperatively. Tumor tissue was collected 
perioperatively and snap frozen in liquid nitrogen (“fresh frozen”) and stored at -80 
degree celcius. Clinicopathological information regarding age, parity, menopausal 
status, FIGO stage, histological grade and type, and type of treatment provided was 
obtained from medical journals and registered and de-identified by a unique patient ID. 
Histopathological diagnosis was obtained from routine pathology reports for final 
hysterectomy specimen. Follow-up data were collected for at least 5 years. An 
overview of biological samples and applied methods is shown in Figure 6.  
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Paper Biomarker Samples      
Paper I HSF1 28    EH ELISA   
   619    PT ELISA   
   176 lesions/84 patients    Recurrence ELISA 
   8    EH IHC   
   174    Curettage IHC 
   42 lesions/26 patients    PT IHC   
Paper II GDF-15 78    MET IHC   
   256    EH mRNA   
   36 paired samples    PT mRNA   
Paper III PD-L1 689    MET mRNA 
  PD-1 737      
   275 lesions/68 patients      
   273 lesions/74 patients      
   221      
Paper IV MSH6 547      
   731      
   235      
         
              
Figure 6: The figure gives an overview of how many patient samples, what kind of 
patient samples and which methods that were applied in each paper. Patient samples 
have been prospectively collected from 2001-2015. EH: endometrial hyperplasia PT: 
primary tumor MET: metastasis IHC: immunohistochemistry. 
 
The Bergen Biobank for Gynecological Cancer contains tissue samples from patients 
with endometrial hyperplasia, primary tumors and corresponding metastases. Thus, the 
cohort is suitable for investigation and comparison of molecular alterations that may 
be important for cancer initiation and tumor progression. However, the biobank does 
not contain normal endometrial tissue and comparison is made between endometrial 







Tissue microarrays (TMAs) were prepared from formalin fixed and paraffin embedded 
(FFPE) tissue. The area with the most representative tumor was selected from 
hematoxylin and eosin stained slides. In case of heterogeneity the least differentiated 
and densest area was selected. Using a custom made precision instrument (Beecher 
Instrument, Silver Spring, MD, USA) three tissue cylinders (0.6 mm) were punched 
out and mounted in a recipient paraffin block. For metastases and endometrial 
hyperplasias, only one tissue cylinder was punched out.  
TMAs are a time-, tissue- and cost-effective method which also reduces the batch-
effect. However, a major concern of the use of TMAs is that a tissue cylinder of 0.6 
mm in diameter may not be representative of the entire tumor. Especially regarding 
tumor heterogeneity, full sections have been considered gold standard and as for all 
biomarkers clinical implementation relies on validation on full sections (144). 
However, previous studies have demonstrated a good concordance between the 
staining of ER, PR, p53 and epithelial membrane antigen (EMA) in full sections and 
TMAs when using three tissue cylinders (145, 146). Also, a good sensitivity for 
detection of PD-L1 (Paper IV) in TMAs when using three tissue cylinders has been 
demonstrated (147).  
Immunohistochemistry 
TMA slides (5 μm) were cut and dewaxed in xylene and rehydrated in ethanol before 
antigen retrieval (citrate buffer pH 6 or Tris EDTA pH 9) in microwave for 15 min. 
Peroxidase block was applied for 8 minutes before incubation with primary antibody 
(Table 4). The respective secondary antibody (anti-mouse or anti-rabbit) was applied 
for 30 minutes. Following diaminobenzidine (DAB) for 3-8 minutes and 




Table 4: Staining protocol for immunohistochemistry. 
Target Primary antibody Buffer Dilution Incubation 
HSF1 4356, Cell Signaling, Danvers, 
MA, USA 
citrate pH 6 1:100 30 min RT 
PD-L1 E1L3N, Cell Signaling, Danvers, 
MA, USA 
citrate pH 6 1:100 1 hour RT 




1:300 1 hour RT 




1:25 1 hour RT 




1:25 1 hour RT 
RT: room temperature. 
Staining evaluation 
The immunostained sections were reviewed by light microscopy and scored visually 
by a semiquantitive and subjective method. Evaluation of staining was performed by 
two independent observers and blinded for the clinical characteristics and outcome. A 
staining index was calculated as a product of staining intensity (0–3) and area of 
positive tumour cells (1<10%, 2=10%–50% and 3>50%) (148, 149).  
Cut-off for biomarkers 
In paper I for subsequent statistical analyses, indexes were grouped in tertiles, 
considering the size of the subgroups and the number of events in each category. Tertile 
division was selected according to similarity in survival within each tertile. Index 0–4 
was considered low, index 6 intermediate and index 9 was considered high. HSF1 
staining was nuclear for all cases with positive staining. The κ-value was calculated to 
be 0.72 for HSF1 by two independent observers.  
In paper III indexes were grouped in quartiles for PD-L1, considering the size of the 
subgroups and the number of events in each category. Quartile division was selected 
according to similarity in survival in each quartile. The lower quartile corresponded to 
negative (staining index=0) expression only, quartile 2 to 4 were merged together and 
subsequently cut off was negative/positive. Staining for PD-L1 was glandular and 
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mainly cytoplasmic. For PD-L1 the κ-value was calculated to be 0.74 by two 
independent observers. For PD-1, expression was evaluated as positive when >5% of 
stromal staining was detected and the cut-off was negative/positive. The κ-value was 
calculated to be 0.72 for PD-1 by two independent observers. Loss of nuclear staining 
of one of the two mismatch-repair proteins, MSH6 and PMS2 were identified as MSI. 
Positive stromal staining was used as internal control. For MSH6 and PMS2, staining 
was defined as negative when less than 10% glandular staining was observed. In case 
of negative cases with no stromal staining (lack of positive control), full sections were 
stained to determine status as previously described (150). Cases were defined as 
negative and thus MSI if either MSH6 or PMS2 was negative,  
In paper IV, for both curettage and hysterectomy specimen two different cut-offs were 
used for MSH6. Either by two groups, into low=SI 0-4 and high=SI 6-9 or indexes 
were grouped in tertiles, considering the size of the subgroups and the number of events 
in each category, low=SI 0-4, intermediate=SI 6 and high=SI 9. Table 5 gives an 
overview of all cut-offs that have been used in each paper.  
Table 5 Cut-off for biomarkers. 
 SI Low exp SI Intermediate exp SI High exp 
HSF1 (Paper I) 0-4 6 9 
PD-L1 (Paper III) 0  1-9 
PD-1 (Paper III) negative  positive 
MSH6 (Paper IV) 0-4 6 9 
MSH6 (Paper IV) 0-4  6-9 
SI: staining index. Exp: expression. 
Commercially available and validated antibodies for HSF1, PD-L1, PD-1, PMS2 and 
MSH6 were used in previously developed staining protocols, however with 
optimization of antibody dilution and antigen retrieval. The sensitivity and specificity 
of antibodies are debated, however the protocol that is used in our lab has been 
validated and optimized multiple times. For HSF1, PD-L1, PD-1, PMS2 and MSH6, 
we used validated antibodies that have previously been used in publications (119, 124, 
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151-153). In both paper I and IV a significant correlation between mRNA and protein 
level was observed and supports that IHC reflects mRNA level. Due to the possibility 
of unspecific staining, antibodies to detect prognostic and predictive biomarkers are 
debated. To optimize the reliability one can use positive controls and optimize staining 
protocol such as primary antibody dilution, incubation temperature and time. IHC 
allows for spatial and subcellular evaluation of protein expression, however, the 
method is not suitable for presice and objective quantification of protein levels. Other 
methods such as reverse phase protein arrays (RPPA) and mass spectrometry would 
achieve a more accurate measurement of protein levels. However, IHC is less costly, 
and a highly clinical applicable and robust tool to guide treatment when proper 
antibody optimization and validation have been conducted.  
3.1.3 Enzyme-linked immunosorbent assay (ELISA) 
In paper II, human enzyme linked GDF-15 Quantakine ELISA kit (#DGD150, R&D 
Systems, Minneapolis, USA) was used to measure GDF-15 in plasma. According to 
the manufacturer´s instructions, 50 µL plasma sample or standard was added in a 96-
well microplate, coated with a monoclonal antibody specific for human GDF-15, and 
incubated for 2h in room temperature. 200 µL human GDF-15 conjugate was added 
after washing, and incubated for 1 hour in room temperature. The wells were washed 
again before 200 µL of substrate solution were added and incubated for 30 min in room 
temperature protected from light, followed by 50 µL of stop solution. The absorbance 
was measured in a microplate reader at the wavelength of 450 nm, and plasma 
concentration of GDF-15 calculated.  
All plasma samples were retrieved from EDTA-blood vials after centrifuged 2000 
rounds per minute for 10 minutes and stored in -80 ̊C until analyzed. No correlation 
between storage time and plasma levels of GDF-15 was demonstrated. Analysis was 
performed in duplicate for n=102 and blinded for clinical characteristics and outcome. 
The endometrial cancer samples were analyzed in the same run, reducing inter-assay 
variation. The assay has a detection limit of 20 ng/L, an intraassay imprecision of 
10.6% or less, and an interassay imprecision of 12.2% or less (154). 
 49 
ELISA is a commonly used biochemical assay which is robust and thoroughly 
validated. The assay has an adequate intraassay and interassay imprecision and is not 
considerable influenced by other biological substances, such as hemoglobin, heparin, 
albumin and bilirubin (154). Overall, ELISA is a relatively inexpensive and clinical 
applicable method.  
3.1.4 Messenger ribonucleic acid (mRNA) microarray analysis 
Gene expression alterations in relation to HSF1 expression (Paper I) were investigated 
in microarray gene expression data already available from 8 endometrial hyperplasias, 
174 primary endometrial cancers and 42 metastatic endometrial cancer lesions, the 
latter from 26 individual patients. For PD-L1 and PD-1 (Paper III), gene expression 
alterations were also investigated in microarray gene expression data already available. 
A number of 221 of these patients with available gene expression data from primary 
tumors overlapped with protein expression data and were used in subsequent analysis. 
The microarray analysis has been performed prior to this thesis. Briefly, tissue samples 
were snap-frozen in liquid nitrogen stored -80 ̊C for RNA extraction. Hematoxylin and 
eosin stained slides were used to identify areas with high tumor cell content 
(preferably>80%, minimum 50% tumor purity). RNA was extracted from unstained 
slides using the RNeasy Mini Kit (Qiagen, Hilden, Germany), hybridized to Agilent 
Whole Human Genome Microarrays 44k (cat. no. G4112F) according to the 
manufacturer’s instructions, and scanned using the Agilent Microarray Scanner Bundle 
(Agilent, Santa Clara, CA, USA). Expression data were normalized using quantile 
normalization. Median spot signal was used as intensity measure. Normalisation of raw 
data and expression analyses were performed using the J-Express software (Molmine, 
Bergen, Norway).  
Tissue with the highest tumor purity was intentionally selected for RNA extraction. 
However, an association with high tumor purity and aggressive endometrial cancers 
has been demonstrated (155). This may lead to a selection bias of the most aggressive 
cancers for gene expression analysis, and gene expression data may not be transferable 
to a routine clinical setting. It therefore needs to be emphasized that gene expression 
analysis performed by RNA extraction needs to be verified by other methods and in 
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true population-based series prior to potential implementation in the clinic. However, 
the Bergen Biobank for Gynecological Cancer contains population-based and 
prospectively collected patient samples with detailed clinical records, FFPE sections 
and a large number of overlapping fresh tissue samples, which gives a unique 
opportunity for investigation of overlapping samples.  
Gene expression analyses 
Significance Analysis of Microarray (SAM) was used in Paper I and III to identify 
genes differentially expressed between groups. Gene Set Enrichment Analysis (GSEA) 
to identify gene sets differentially expressed between groups was applied in Paper III 
and was performed applying gene sets from Molecular Signatures Database (MSigDb, 
version 6.2). All analyses were performed using the J-Express software (Molmine, 
Bergen, Norway). 
Connectivity Map 
Connectivity Map (http://www.broadinstitute.org/cmap/) is a publically available 
database that aims to establish a relation among disease, physiological processes, and 
the action of drugs (156). The drug signatures are generated before and after treating 
cell lines with different drugs. By applying gene signatures representing a biological 
state to the Connectivity Map database, a “connectivity score” is provided with the top 
ranked compound signatures correlated and anti-correlated to the gene signature that 
was applied. The method was used in Paper I.  
Connectivity Map provide useful information, however, not without limitations. The 
changes in expression are based on cell lines from breast cancer, prostate, leukemia 
and melanoma (156), thus it may affect the results that the cell lines are not of 
endometrioid origin. Also, a fundamental limitation is that cell lines constitute a more 
simple system compared to a complex cancer in vivo, and the gene expression caused 
by the microenvironment is not taken into consideration (157). Overall, Connectivity 
Map is time-efficient and useful as a hypothesis-generating tool.  
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3.1.5 Statistical methods 
Statistical analysis was conducted applying Statistical Program for the Social Sciences, 
version 21, 24 and 25 (IBM Inc. Chicago, IL, USA). All p-values were two sided and 
p-value of less than 0.05 was considered statistically significant. Pearson Chi-square 
and Fisher exact test were used for comparison between categorical data. Univariate 
survival analysis was performed using the Kaplan-Meier method and log-rank test, 
grouping low versus high concentration. Disease-specific survival was defined as time 
from primary treatment to death from endometrial cancer. Patients who died from other 
causes or were lost to follow-up were censored at the date of death/last follow-up. 
Differences in survival between groups were estimated by the log-rank (Mantel–Cox) 
test. Variables were visually examined by a log-minus-log plot to check the 
assumptions about proportionality over time, and tested for potential interactions 
before inclusion in the multivariate proportional hazards regression models (Cox 
analyses). Unadjusted and adjusted hazard ratios were calculated as measures of effect. 
Significance of change in protein expression from primary tumors to corresponding 
metastatic lesions was evaluated using Fisher’s exact and Wilcoxon’s signed-rank tests. 
Non-parametric tests Mann Whitney U and Wilcoxon Signed Rank were used for 
comparison of continuous data between study groups. Binary logistic regression was 
used to evaluate the odds ratio (OR) for lymph node metastases and recurrence.  
3.1.6 Approvals 
The Norwegian Data Inspectorate, Norwegian Social Sciences Data Services (15501) 
and Western Regional Committee for Medical and Health Research Ethics (REK 




















4. Summary of results  
Paper I  
We explored 28 endometrial hyperplasias, 619 primary tumors and 176 metastatic 
lesions from 84 corresponding primary tumors for protein expression of HSF1 by 
immunohistochemistry in formalin fixed paraffin-embedded (FFPE) tissue. 
Transcriptional alterations related to HSF1 protein level were investigated by mRNA 
microarray analysis for 224 freshly frozen samples. We found that high expression of 
HSF1 of protein and mRNA levels in endometrial cancers reflect aggressive 
phenotype. High expression of HSF1 was significantly associated with high age, non-
endometrioid histological type, high grade and aneuploidy (all p-values <0.02). Among 
the ERα-positive patients, high HSF1 was significantly associated with non-
endometrioid type, high grade and aneuploidy (all p-values <0.004). The same pattern 
was seen for the ERα-negative patients. In ERα-positive patients, HSF1 was an 
independent prognostic marker. HSF1-related gene signatures were associated with 
poor survival and increase during disease progression. HSP90 inhibitors were 
suggested as targeted therapy.  
Paper II 
In this study, we included plasma samples from 78 patients with hyperplasias, 235 with 
endometrial carcinomas and 36 corresponding patients with recurrence. We 
demonstrated that high plasma level GDF-15 is associated with poor prognosis and 
shorter time to recurrence. High plasma level was significantly associated with high 
age, high FIGO-stage, non-endometrioid type, high grade and myometrial infiltration 
(all p-values <0.003) Also, in patients with a presumed low-risk stratification high 
plasma levels GDF-15 predict aggressive disease. In plasma samples from patients at 
time of primary treatment, the preoperative level of plasma GDF-15 was significantly 
higher for patients who later experienced recurrence than for patients who did not 
develop recurrent disease. For these patients, with available paired samples, plasma 
levels of GDF-15 at recurrence were significantly higher than plasma levels of GDF-
 54
15 measured at time of primary diagnosis. In regression analysis, GDF-15 is an 
independent marker for lymph node metastases and recurrence.  
Paper III  
We explored the expression patterns of PD-L1 and PD-1 in FFPE tissue from 689 and 
737 primary tumors, respectively. 275 corresponding metastases from 68 patients were 
explored for protein expression of PD-L1 and 273 corresponding metastases from 74 
patients were explored for protein expression of PD-1. In primary tumors, PD-L1 and 
PD-1 are expressed in 59% and 63%, respectively, but have no impact on survival, nor 
when stratified for MSS and MSI. Expression patterns of PD-L1 and PD-1 are similar 
across MSS and MSI tumors. Available corresponding metastatic lesions show 
heterogeneous expression of PD-L1 and PD-1 compared to primary tumors, and a 
considerable intra-variable expression. Gene expression analysis was performed in an 
already available dataset with 221 patients revealing upregulation of several genes 
related to immunological activity, including CD274 (encoding for PD-L1), in PD-1 
positive tumors.  
Paper IV 
Elevated levels of mRNA MSH6 demonstrated poor survival where patients with high 
MSH6 had a 5-year survival of 65% compared to 93% in patients with low MSH6 
(p<0.001). To further confirm the prognostic value of MSH6, 547 curettage specimen 
and 731 hysterectomy specimen were investigated for protein expression of MSH6. 
High expression of MSH6 was associated with high age, FIGO stage III-IV, non-
endometrioid type, high grade and lymph node metastasis in hysterectomy. In survival 
analysis, high expression of MSH6 was associated with poor survival (p<0.001). The 
same pattern was seen in curettage specimen. In curettage specimen high expression of 
MSH6 was associated with high age, FIGO stage III-IV, non-endometrioid type, high 
grade, lymph node metastasis and deep myometrial infiltration. High expression of 
MSH6 was associated with poor survival (p<0.001). MSH6 was an independent 
prognostic marker preoperatively, adjusted for age, histological risk-classification and 
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hormone receptor status. Also, in patients with a putative low-risk stratification 























5. Discussion of results 
A key challenge in tailoring cancer treatment is to identify high-risk from low-risk 
patients. In order to do so, biomarkers are crucial. The incidence of endometrial cancer 
is increasing, and in spite of an overall favorable prognosis, 15-20% of patients 
experience recurrence (4). Prognostic markers in order to better predict prognosis, and 
predictive markers for response to treatment and targeted therapy are of paramount 
importance to improve treatment of endometrial cancer. For a biomarker to be of 
clinical interest, it must add valuable information in addition to what is already known 
from established clinicopathological variables or predictors. Biomarkers can be 
measured in serum, plasma or urine, but more invasive techniques requiring tumor 
tissue, such as immunohistochemistry and DNA/RNA analyses are widely used (129). 
The Bergen Biobank for Gynecological Cancer contains tissue samples from patients 
with endometrial hyperplasia, primary tumors and corresponding metastases. The large 
biobank gives a unique opportunity to study biomarkers in a large patient cohort.  
In this thesis, which contains four papers, the overall aim was to explore biomarkers, 
both tissue- and plasma markers that better predict prognosis and guide therapy. We 
aimed to evaluate the prognostic impact of the tissue marker HSF1 (Paper I), identify 
plasma GDF-15 as a marker for recurrent disease and to validate GDF-15 as a 
prognostic marker for aggressive disease and as an independent marker for lymph node 
metastases (Paper II). We also aimed to determine the expression patterns of PD-L1 
and PD-1 in tissue from both primary tumors and corresponding metastatic lesions, 
stratified for microsatellite instable and microsatellite stable cancers (Paper III). 
Further, we aimed to define the prognostic value of MSH6 in tissue from curettage and 
hysterectomy specimens (Paper IV). We here present prognostic value of HSF1, GDF-
15 and MSH6, and demonstrate a frequent expression of PD-L1 and PD-1 with a 
discordant expression in metastatic lesions. Overall, our results contribute to a step 
towards improved risk-stratification in endometrial cancer in order to improve clinical 
decision-making.  
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5.1 Prognostic markers in order to better identify high-risk 
patients 
High HSF1 protein level associates with aggressive endometrial cancer, also in ER-
positive patients 
High protein level of HSF1 demonstrated poor survival and was associated with 
aggressive clinical characteristics in endometrial cancer patients (Paper I). However, 
the exact role of HSF1 in endometrial cancer is still not fully elucidated and its role as 
a prognostic marker needs to be further explored. In cancer in general, the role of HSF1 
has become increasingly relevant, and it is evident that HSF1 plays a role in cell-
proliferation, anti-apoptosis, epithelial-mesenchymal transition, migration and 
invasion of cancer cells, and metastasis (106, 158). Increasing evidence has supported 
that HSF1 plays a role in tumorigenesis,  by expression of heat shock proteins to protect 
proteins from degradation that are essential to tumorigenesis (104). Other findings 
suggest that HSF1 supports malignant transformation by controlling core cellular 
functions such as proliferation, survival, protein translation and glucose metabolism 
(108). The relevance of HSF1 as a prognostic biomarker has been demonstrated in 
several cancers, such as hepatocellular carcinoma and colorectal cancer (159, 160). 
Interestingly, in breast cancer, a cancer type with many similarities to endometrial 
cancer, HSF1 has been suggested as a key regulator of carcinogenesis, and high levels 
of HSF1 protein have been related to poor survival (105). We found a significant 
increase of protein expression of HSF1 from primary to metastatic lesions. This 
supports previous findings that HSF1 plays a role in promoting migration and invasion 
of cancer cells and metastasis (158). 
High HSF1 was associated with poor survival in both ER-positive and ER-negative 
patients. Although more research is needed to fully understand the interplay between 
HSF1 and ER, this may suggest that HSF1 can identify a subgroup of patients with ER-
positive tumors who could benefit from adjuvant therapy, despite being regarded as 
having a favorable prognosis. Interestingly, HSF1 has been proposed as an inhibitor of 
estrogen-dependent transcription which supports our findings of HSF1 as an 
independent prognostic marker within ER-positive patients (161). However, high 
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HSF1 is also associated with poor survival in ER-negative patients, which is in line 
with cell line studies where depletion of HSF1 was found to reduce the malignant state 
of the cell regardless of ER status (108).  
High plasma level GDF-15 identifies patients with poor prognosis also in putative low-
risk patients 
Biomarkers derived from blood samples are easier to obtain compared to tissue 
biomakers. The sampling is less invasive, and the biomarker can be measured 
repeatedly during the course of the disease. In endometrial cancer, there is a need to 
preoperatively identify patients with aggressive disease. We demonstrate independent 
prognostic impact of GDF-15 measured in plasma from preoperative blood samples 
(Paper II). Previous findings support the role of GDF-15 as a biomarker in endometrial 
cancer and demonstrate the role of GDF-15 as a marker for aggressive disease and 
lymph node metastases (162). Our findings are in line with this, however we also 
demonstrate prognostic impact in patients with putative low-risk disease. Further, 
GDF-15 is an independent predictor of recurrent disease, when adjusting for age, 
histology and MI. Previously, GDF-15 has been proposed as a marker for 
discrimination between uterine sarcomas and benign leiomyomas, further emphasizing 
the association with GDF-15 as an indicator of malignancy (163, 164). The role of 
GDF-15 has been widely studied in other cancers and previous findings have shown 
overexpression in malignant melanomas, prostate-, pancreatic- and colonic cancers 
(165-168). Although the function of GDF-15 in cancer is not fully understood, it is 
known that GDF-15 can affect cell proliferation, differentiation, apoptosis, invasion 
and metastases (169). However, GDF-15 has been deemed as an unspecific marker and 
has also been suggested as a predictor of poor outcome in cardiovascular disease and 
after cardiac arrest (170, 171). Interestingly, in breast cancer recent findings reveal 
downregulation of GDF-15 by silencing of ras suppressor-1 (RSU-1) and other 
proteins related to invasion and metastasis (172). Further, GDF-15 has been suggested 
to reflect the characteristics of the tumor microenvironment and has been proposed as 
a marker for cytokine production and immune infiltration at the tumor site in breast 
cancer (173). 
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A molecular marker for lymph node metastasis, which can guide which patients to 
assign for lymphadenectomy is useful when planning the surgical procedure. To spare 
a patient from the morbidity of undergoing lymphadenectomy if unnecessary is 
valuable. Interestingly, GDF-15 was superior to preoperative histological risk 
classification in predicting metastatic lymph nodes (Paper II). Our results suggest that 
GDF-15 can predict lymph node metastasis, which is supported by previous findings 
(162). The sentinel lymph node technique as alternative to traditional 
lymphadenectomy has become increasingly interesting in endometrial cancer, 
demonstrating a high degree of diagnostic accuracy in detecting lymph node metastases 
(60). However, the technique is still not implemented in most countries and there are 
limitations related to obesity. Hormone receptor status is currently studied (in the 
clinical implementation study MoMaTEC2, NCT02543710), this is one example of the 
clinical relevance of molecular markers to guide lymphadenectomy. PET-CT has 
demonstrated a satisfying accuracy in predicting lymph node metastases (40, 174), but 
this imaging method is not yet incorporated in routine clinical use. A plasma marker to 
assist preoperative risk-stratification, such as GDF-15 could thus be useful in the 
preoperative work-up.  
5.2 Markers for targeted therapy to tailor treatment 
HSP90 inhibitors as targeted therapy in patients with high HSF1 protein level 
Predictive markers are needed to tailor therapy and targeted treatment. We suggested 
HSP90 inhibitors as potential targeted therapy in patients with high HSF1 protein level 
(Paper I). Targeting HSP90 in cancer has become increasingly interesting and has 
demonstrated promising response rates and durable results (175). HSP90 inhibitors 
have been suggested as treatment in combination with carboplatin and paclitaxel for 
recurrent and advanced ovarian cancer (176). A recent study revealed the potential of 
HSP90 inhibitors to platinum-resistant endometrial cancer that overexpress the 
phosphoglycerate kinase 1 (PGK1), which mediates DNA repair and methylation 
through the HSP90/ERK pathway (177). Combined inhibition of AKT and HSF1 has 
demonstrated efficacy in vitro and in vivo in breast cancer (178). However, HSP90 as 
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a druggable target in endometrial cancer needs to be further explored in bigger and 
more robust studies both in vitro and in vivo.  
High expression of MSH6 identifies aggressive endometrial cancers 
The identification of the four molecular subtypes with prognostic significance in 
endometrial cancer by TCGA has led to an improved understanding of the molecular 
landscape of endometrial cancer (89). A more pragmatic approach to applying 
molecular biomarkers for risk stratification has been proposed, and both the 
TransPORTEC and the ProMisE initiatives have developed a more clinical applicable 
method (119, 120, 124, 179). The increased interest of MSI as one of the molecular 
subgroups for risk-stratification, and the defining of this subgroup by the mismatch 
repair proteins MSH6 and PMS2, has also led to the relevance of MSH6 as a prognostic 
marker in endometrial cancer. We demonstrate an association with high expression of 
MSH6 and poor survival in endometrial cancer (Paper IV). Supporting the role of 
MSH6 as a prognostic marker in endometrial cancer, are previous findings 
demonstrating independent prognostic impact of MSH6 in a cohort of 243 endometrial 
cancer patients (180). High expression of MSH6 has demonstrated a role of increased 
proliferation, migration and invasion in glioblastoma (181). Co-overexpression of 
MSH2 and MSH6 has resulted in several genome instability phenotypes, causing 
increased mutation rates, elevated loss of heterozygosity and increased sensitivity to 
DNA replication inhibition and DNA-damaging agents (182).  Interestingly, high 
expression of MSH6 has been linked to poor survival in oral squamous cell carcinoma 
and prostate cancer (183, 184). In malignant melanoma, elevated levels of both mRNA 
and protein expression have been associated with aggressive clinical features and poor 
prognosis (185, 186). This support our results, where high gene- and protein expression 
of MSH6 were to associate with aggressive disease. We demonstrate independent 
prognostic impact of MSH6 preoperatively, adjusted for age, preoperative risk-
stratification and hormone receptor status. Also, in patients with a putative low-risk 
stratification MSH6 identifies patients with a poor prognosis. The prognostic impact 
was validated in both curettage and hysterectomy specimen. mRNA levels 
corresponded to protein levels determined by IHC. This demonstrates an added value 
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of determining MSI by immunohistochemically staining of MSH6 and PMS2 
according to the ProMisE classifier which is on the verge of clinical implementation 
(119, 124). However, to identify patients with aggressive disease, evaluation of staining 
intensity of MSH6 by scoring index is crucial to identify patients with poorer survival 
and need for adjuvant treatment or closer follow-up.  
Predictive markers to guide therapy with immune checkpoint inhibitors 
To date, no targeted therapy is implemented in clinical practice for endometrial cancer 
patients. The PD-1 antibody, pembrolizumab was granted FDA approval in 2017 for 
treatment of MSI-high cancers regardless of tumor type (143), and PD-L1 and PD-1 
expression in endometrial cancer has been of increasing interest. Therapy with 
pembrolizumab to MSI-high recurrent and metastatic endometrial cancer has 
demonstrated promising results (97). The PD-1/PD-L1 pathway has been extensively 
studied in cancer in general (187). However, the expression pattern of PD-L1 and PD-
1 has not been thoroughly explored in endometrial cancer. The reported fraction of PD-
L1 and PD-1 positive tumors has been inconsistent and investigated in small cohorts 
(188-190). We identified high expression rates of PD-L1 and PD-1 in endometrial 
cancer, 59% and 63%, respectively (Paper III). We show similar expression pattern 
of PD-L1 and PD-1 across MSS and MSI tumors indicating that not only patients with 
MSI-high tumors may be eligible for treatment with immune checkpoint inhibitors. 
Previous studies have shown more frequent expression of PD-L1 in MSI tumors 
compared to MSS tumors (190, 191). However, recent clinical studies have indicated 
that MSI-status may not be definite for response to immune checkpoint inhibitors. A 
recent trial demonstrated efficacy when combining pembrolizumab and lenvatinib 
multikinase inhibitor of VEGFR 1-3 in metastatic endometrial cancer, and an objective 
response was recorded in 16/45 patients with MSS-tumors compared to two out of four 
MSI-tumors (99). Also, a study testing combination therapy with dostarlimab (PD-1-
inhibitor) and chemotherapy (carboplatin and paclitaxel), regardless of MSI-status 
(NCT03981796) is in the pipeline and the results from this trial will hopefully indicate 
if also MSS patients are responders. Still, the robustness of PD-L1 and PD-1 as 
predictive markers for response to immune checkpoint inhibitors is debated, as studies 
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have shown a variable predictive value of PD-L1 (97, 192). Interestingly, gene 
expression analyses of all patients with expression of PD-1, regardless of MSI, 
identified upregulated genes related to immune activity, including the gene CD274 
(encoding for PD-L1), further emphasizing the immunological activity in patients with 
PD-1 positive tumors. 
Expression of PD-L1 and PD-1 in corresponding metastases is intra-variable and 
discordant to primary tumors 
Evaluation of expression of PD-L1 and PD-1 in metastases is of particular importance 
as treatment with immune checkpoint inhibitors is of foremost relevance in metastatic 
endometrial cancer. Interestingly, we reported a considerable intra-variable expression 
in metastatic lesions and a discordant expression from primary tumors to metastatic 
lesions (Paper III). Previous studies have found frequent expression of PD-L1 in 
metastatic colorectal cancer compared to primary tumors and an increase of PD-L1 
during disease progression (193). Also, discordant expression between primary tumors 
and corresponding metastatic lesions has previously been demonstrated in breast 
cancer, malignant melanoma and head and neck cancers (194-196). Although treatment 
with pembrolizumab to PD-L1 positive, advanced endometrial cancer patients has 
previously demonstrated durable antitumor activity (97), a variation in response was 
noted and heterogeneity was deemed as a possible explanation in cases where there 
was a lack of response. The observed variation in PD-L1 and PD-1 expression in the 
metastases might thus be relevant for the response to treatment, also in endometrial 
cancer. Further studies to explore PD-L1 and PD-1 expression in metastatic lesions 
prior to treatment would be interesting to determine the ability of these biomarkers to 
predict response to checkpoint inhibitors.  
Implementation of a biomarker from basic research, to pre-clinical development and 
clinical development is a demanding and time-consuming process (127). In 
endometrial cancer, the process has been slow and although several biomarkers have 
been identified in endometrial cancer, few of them have changed clinical routines 
(197). However, a small step is the local initiative MoMaTEC2 (NCT02543710). 
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Based on the findings from MoMaTEC1, an international multicenter study, which 
demonstrated that combined loss of ER and PR in pre-operative curettage predicted 
lymph node metastases and poor survival (139). MoMaTEC2 includes low-risk patients 
with positive hormone receptor status for both ER and PR to omit lymphadenectomy. 
High-risk endometrial cancer with either negative ER or PR will undergo 
lymphadenectomy. Until recent years, randomized trials have been the gold standard 
of clinical research, however the need for a large sample size, long study duration and 
the costs have been some of the shortcomings (198). Histological type has primarily 
been the known determinant of drug responsiveness and cancer drugs have previously 
been developed separately for different histological types of tumors. However, this 
focus has in recent years been supplemented with focus on genomic alterations in the 
tumor. To investigate the efficacy of targeting genomic alterations that occur across a 
wide variety of tumor types, basket trials are best suited (199, 200). Umbrella trials 
maintain the focus on single histology, as for traditional clinical trials, however, 
umbrella trials stratify treatment based on prespecified genomic biomarkers (200). 
These biomarker-guided clinical studies are important tools to continue making 
progress in the field.  
In this thesis, the overall aim was to explore biomarkers that better predict prognosis 
and guide therapy. HSF1 demonstrated prognostic impact and was interestingly an 
independent marker for poor prognosis within ER-positive patients, a patient group 
with a presumed favorable prognosis. For patients with high expression of HSF1, we 
suggested HSP90 inhibitors for targeted therapy (Paper I). However, for disease 
monitoring during follow-up, GDF-15 demonstrated independent impact as a predictor 
of recurrent disease. GDF-15 also identified patients with poor prognosis within a 
subgroup of patients with a putative low-risk stratification. Interestingly, GDF-15 was 
superior to histological risk classification in predicting metastatic lymph nodes and can 
be helpful in the diagnostic work-up when deciding when to assign the patient for 
lymphadenectomy (Paper II). However, GDF-15 is an unspecific marker, potentially 
biased by cardiovascular disease. The identification of patients with MSI-tumors and 
expression of PD-L1 and PD-1 opens doors to treatment with immune checkpoint 
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inhibitors (Paper III). The demonstrated discordant and intra-variable expression of 
PD-L1 and PD-1 in metastatic lesions and evaluation of PD-L1 and PD-1 prior to 
assigning the patient to treatment with immune checkpoint inhibitors are important for 
further evaluation of the predictive value of PD-L1 and PD-1. Evaluation of MSI-status 
in endometrial cancer by IHC staining for PMS2 and MSH6, reveals potential of MSH6 
as a prognostic marker in endometrial cancer when using staining index for evaluation 
of protein expression. MSH6 adds value as an independent prognostic marker 
preoperatively both in the overall patient group, and can also identify patients with 
poorer survival within a subgroup of patients with a putative low-risk disease (Paper 
IV).  
Validation in large patient cohorts and clinical studies to determine the potential of 
HSF1, GDF-15 and MSH6 is needed. The relevance of PD-L1 and PD-1 as predictive 
markers for response to immune checkpoint inhibitors in endometrial cancer needs to 
be further evaluated in clinical trials. However, the identification of these biomarkers 















Paper I: High expression of HSF1 is associated with aggressive disease and predicts 
poor survival. We suggest HSP90 inhibitors for targeted therapy.  
Paper II: High plasma levels of GDF-15 is associated with poor survival and is an 
independent marker for recurrent disease and lymph node metastases.  
Paper III: PD-L1 and PD-1 are frequently expressed in primary tumors and expression 
is similar across MSS and MSI-tumors, but PD-L1 and PD-1 do not have prognostic 
impact. We demonstrate a considerable intra-variable expression in corresponding 
metastatic lesions and a discordant expression form primary tumors to corresponding 
metastatic lesions.   
Paper IV: High mRNA level and protein expression of MSH6 are associated with 
aggressive disease and predict poor survival in both curettage and hysterectomy 
specimen. MSH6 also identifies patients with poor prognosis in patients with a putative 
low-risk stratification preoperatively. MSH6 is an independent marker for poor 





















7. Future perspectives 
Novel and robust biomarkers for clinical use is an urgent need in order to better detect 
high-risk from low-risk patients. Predictive markers to better predict response to 
therapy are crucial to improve disease management and individualize therapy. To date 
no prognostic markers have been implemented for routine clinical use. In this thesis we 
have suggested some possible solutions. The following points are suggested follow-up 
studies. 
By gene expression analysis we suggested HSP90 inhibitors as targeted therapy. The 
role of HSP90 inhibitors in endometrial cancers should be determined in studies in vitro 
and in vivo.   
GDF-15 can add value to clinical practice in order to monitor disease development 
during follow-up. Studies to further determine the ability of GDF-15 in predicting and 
monitoring recurrence would be of high interest. The role of GDF-15 as a highly 
clinical applicable plasma marker should be determined in clinical studies.  
Efforts should be made to implement MSI-status in clinical practice for endometrial 
cancer, both due to the value of MSI as a risk-stratifier and the potential predictive 
value of MSI for response to immune checkpoint inhibitors. To add to the clinical 
relevance of MSI-status for endometrial cancer, staining of MSH6 should be evaluated 
by staining index to further define the role of MSH6 as a marker for poor prognosis. 
Further studies exploring PD-L1 and PD-1 expression in corresponding metastatic 
lesions compared to the primary tumor prior to treatment, would be interesting to 
determine the heterogeneity of PD-L1 and PD-1. The predictive value of PD-L1 and 
PD-1 and the efficacy of PD-L1 and PD-1 inhibitors in endometrial cancer should be 
evaluated in clinical studies. More research is needed to determine if combination 
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Better biomarkers are needed in order to identify patients with endometrial carcinoma at risk
of recurrence and who may profit from a more aggressive treatment regimen. Our objective
was to explore the applicability of plasma growth differentiation factor 15 (GDF-15) as a
marker for recurrent disease, as well as a marker for poor prognosis and lymph node
metastases.
Methods
EDTA-blood samples were obtained from 235 patients with endometrial cancer before pri-
mary surgery. For 36 of these patients, matching blood samples were collected at time of
recurrence. Blood samples were also collected from 78 patients with endometrial hyperpla-
sia. Plasma GDF-15 was measured by an enzyme-linked immunosorbent assay (ELISA).
Preoperative pelvic MRI scans for 141 patients were investigated in parallel for imaging
variables.
Results
Preoperative plasma level of GDF-15 was significantly higher for patients who experienced
recurrence (1780 ng/L; 95% CI; 518–9475 ng/L) than for patients who did not develop recur-
rent disease (1236 ng/L; 95% CI; 307–7030 ng/L) (p<0.001). Plasma levels of GDF-15 at
recurrence (2818 ng/L, 95% CI 2088–3548 ng/L) were significantly higher than plasma lev-
els of GDF-15 measured at time of primary diagnosis (1857 ng/L, 95% CI; 1317–2398 ng/L)
(p = 0.001). High plasma level GDF-15 independently predicts recurrent disease (OR =
3.14; 95% CI 2.10–4.76) and lymph node metastases (OR = 2.64; 95% CI 1.52–4.61).
Patients with high plasma level of GDF-15 had significantly larger tumor volume (p = 0.008).
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Conclusion
Elevated plasma level of GDF-15 is associated with aggressive disease and lymph node
metastasis in endometrial carcinoma. GDF-15 may be helpful in indicating recurrent disease.
Introduction
Endometrial cancer is the most common gynecologic malignancy and the fourth most com-
mon cancer among women in industrialised countries. Incidence is increasing worldwide,
mostly due to the obesity epidemic. The prognosis is good with an overall 5-year survival of
80%, however 15–20% of patients with a presumed low risk disease experience recurrence [1].
Better biomarkers are thus needed in order to identify patients at high risk of recurrence who
may profit from a more aggressive treatment regimen. To date there are no biomarkers for
prognosis routinely available or in widespread use in the clinic and the majority of suggested
markers have been developed for immunohistochemistry based detection in patient tissue
biopsies. However, there has been little focus on identifying markers in preoperative blood
samples [2–4]. Such markers are less invasive than those from biopsy, easily obtainable and
could also be measured repeatedly during the course of the disease. A robust prognostic
plasma biomarker would therefore potentially be highly valuable in the clinic.
Growth differentiation factor-15 (GDF-15), is a distant member of the transforming growth
factor (TGF)-beta superfamily, also named macrophage-inhibitory cytokine -1 (MIC-1), and
was originally identified in activated macrophages [5]. The TGF-beta superfamily has a role in
regulating inflammatory and apoptotic pathways in injured tissues and during disease pro-
cesses. GDF-15 is associated with cell cycle arrest and apoptosis [6]. Expression is dramatically
increased in diseased states, such as acute injury, inflammation and cancer [7]. The prognostic
value of GDF-15 is previously explored in cardiac disease, during pregnancy and in cancer. It
has been suggested as a prognostic biomarker where increased GDF-15 is associated with
increased risk of death at 1 year in patients with non-ST-elevation acute coronary syndrome [8]
as well as in patients with ST-segment elevation and myocardial infarction [9]. In the placenta
GDF-15 is physiologically highly expressed [10] and low expression of GDF-15 is associated
with miscarriages [11]. Elevated levels, however, are associated with diabetes mellitus and pre-
eclampsia [12]. In cancer, GDF-15 overexpression has been reported in malignant melanomas,
prostate-, pancreatic- and colonic cancers [13–16]. Furthermore, elevated serum levels of GDF-
15 are linked to cancer-associated anorexia and weight loss in prostate cancer [17]. In gyneco-
logical malignancies GDF-15 is reportedly an independent marker of aggressive disease in ovar-
ian cancer [18]. For uterine sarcomas, elevated GDF-15 may aid in discriminating aggressive
sarcomas from benign leiomyomas [19], whereas for endometrial cancer increased GDF-15
expression has been reported to predict lymph node metastases and poor survival [20].
In the present study we wanted to explore the applicability of GDF-15 in predicting endo-
metrial carcinoma recurrence. In addition, using an extensive panel of clinicopathological var-
iables including survival, our aim was to validate GDF-15 as a prognostic marker in
endometrial carcinoma and as a possible predictor of lymph node metastases.
Materials and methods
Patient samples
EDTA-blood samples were obtained preoperatively from 235 patients with endometrial cancer
before primary surgery. During time of follow-up 48 patients developed recurrence and blood
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samples were collected from 36 of these patients at time of recurrence. In addition, EDTA-
blood was collected from 78 patients diagnosed with endometrial hyperplasia. All patients
have been diagnosed at Haukeland University Hospital, Norway between 2003 and 2014 and
clinical data as well as blood samples were prospectively collected. Patients signed informed
consent. Regional Committees for Medical and Health Research Ethics approval: 2009/2315
and 2014/1907. The median follow-up in this cohort is 43 months (range 1–189). Blood sam-
ples were centrifuged at 1600 g for 15 min and the plasma was stored at– 80 ˚C until measure-
ment of GDF-15. Distribution of measured GDF-15 plasma level was not influenced by
storage time.
Additionally, data regarding GDF-15 plasma levels were also locally available from an inde-
pendent cohort of 466 endometrial cancer patients previously published [20]. In order to
improve statistical power when predicting lymph node metastases and recurrence, the data
were merged together with the current cohort when performing regression analyses. Data
were missing for recurrence from 47 patients, histological type from 47 patients and myome-
trial infiltration from 49 patients, and the resulting cohort included 603 patients. Regarding
lymph node status, data were missing for 190 patients and preoperative histology missing for
65 patients, and the cohort included 495 patients.
GDF-15 measurements
GDF-15 in plasma was measured by the Human enzyme linked GDF-15 Quantakine ELISA
kit (#DGD150, batch #P153423, R&D Systems, Minneapolis, USA). The ELISA was performed
according to the manufacturer´s instructions. Briefly, 50 μL plasma sample or standard was
added in a 96-well microplate coated with a monoclonal antibody specific for human GDF-15,
and incubated for 2h in room temperature. Following washing, 200 μL human GDF-15 conju-
gate was added and incubated for 1 hour in room temperature. The wells were washed again
before 200 μL of substrate solution were added and incubated for 30 min in room temperature
protected from light, followed by 50 μL of stop solution. The absorbance was measured in a
microplate reader at the wavelength of 450 nm, and plasma concentration of GDF-15 calcu-
lated. To confirm reproducibility, a subset (n = 102) were measured in duplicates. Clinical data
were blinded while performing and evaluating laboratory investigations. The assay has a detec-
tion limit of 20 ng/L, an intraassay imprecision of 10.6% or less, and an interassay imprecision
of 12.2% or less [21].
Preoperative magnetic resonance imaging (MRI)
In parallel, preoperative pelvic MRI scans for 141 patients were assessed to derive the following
imaging variables: endometrial tumor size, signs of deep myometrial invasion, cervical stroma
invasion and lymph node metastases. MRI was conducted on a whole body 1.5-T MRI system
(Siemens Avanto running Syngo v. B17, Erlangen, Germany) using a six channel body coil
applying a standardized imaging protocol [22]. To reduce motion artefacts 20 mg of butylsco-
polamine bromide (Buscopan; Boehringer, Ingelheim, Germany) was administered intrave-
nously. Mean time (range) between MRI examination and surgical staging was 1.5 (0–12)
weeks.
Statistical analyses
Statistical analyses were conducted applying Statistical Program for the Social Sciences (SPSS),
version 24 (IBM Inc. Chicago, IL, USA). All p-values were two sided and p-value of less than
0.05 was considered statistically significant. Pearson Chi-square or Fisher exact test were used
for categorical data. Univariate survival analysis was performed using the Kaplan-Meier
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method and log-rank test, grouping low versus high concentration. Cut-off values for categori-
zation were based on tertiles according to the size of the subgroups and the number of events
in each category. The two lower GDF-15 tertiles were merged due to similar survival. Cut-off
value based on this method was found to be near identical to our previous study [20] (cut-off
in previously published cohort: 1400 ng/L, cut-off in this cohort 1418 ng/L). For analyses
where the cohorts were merged, cut-off value was 1418 ng/L. Low-risk patients were defined
as endometrioid histologic type and grade 1 and 2 disease, and high risk patients as endome-
trioid grade 3 and non-endometrioid. Disease-specific survival was defined as time from pri-
mary treatment to death from endometrial cancer. Patients who died from other causes or
were lost to follow-up were censored at the date of death/last follow-up. Non-parametric tests
Mann Whitney U or Wilcoxon Signed Rank were used for comparison of continuous data
between study groups. Binary logistic regression was used to evaluate the odds ratio (OR) for
lymph node metastases and recurrence.
Results
Plasma GDF-15 associates with poor survival, also in low-risk patients
To validate previous observations that plasma level of GDF-15 is a biomarker for poor progno-
sis in endometrial cancer, plasma level of GDF-15 was determined in an independent patient
population including 235 patients with primary endometrial carcinoma. High level of plasma
GDF-15 was associated with reduced disease-specific survival (p = 0.001, Fig 1A) with 5-year
survival rate of 72.9% compared to 94.1% in patients with low GDF-15. In addition, high
GDF-15 indicated reduced recurrence-free survival (p<0.001, Fig 1B) with 5-year recurrence-
free survival rate of 61.2% compared to 89.3% in endometrial cancer. GDF-15 level was signifi-
cantly higher in patients aged >66 years, and in patients with advanced FIGO stage, non-
endometrioid histologic subtype, high grade and with deep myometrial infiltration (all p-val-
ues �0.003, Table 1). These findings are in line with previous findings from a separate cohort
from our hospital [20]. To further explore the usefulness of plasma GDF-15, we performed
analyses in the low-risk subgroup of patients, defined by endometrioid histology and grade 1
or 2 disease on preoperative curettage specimen (n = 148). Also in this patient subgroup, high
level of plasma GDF-15 was associated with poor prognosis (p = 0.002, Fig 1C) with a 5-year
survival rate of 72.8% compared to 97% in patients with low GDF-15. High age, high grade
Fig 1. Disease-specific survival (A) and recurrence-free survival (B) in 235 patients illustrated by Kaplan Meier curves. Disease-specific survival
in patients with a putative low-risk disease preoperatively, that is endometrioid grade 1 or 2 (C). P-values are calculated by the Mantel-Cox log
rank test. Low GDF-15 is the two lower tertiles, 1. and 2. combined. High GDF-15 is the 3. tertile. Number of cases are given in each category
and in parenthesis number of disease-specific deaths or recurrence.
https://doi.org/10.1371/journal.pone.0210585.g001
GDF-15 predicts aggressive disease in endometrial cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0210585 January 15, 2019 4 / 13
and deep myometrial infiltration were all associated with high levels of GDF-15 (all p-values
�0.007, Table 2) in low-risk patients. BMI did not correlate with increasing plasma concentra-
tions of GDF-15 (R2 0.003).
Plasma GDF-15 does not distinguish between hyperplasias and
endometrial cancer
As the plasma level of GDF-15 has been reported to be elevated in cancers compared to healthy
controls [20], we investigated if plasma GDF-15 also is a marker for progression from hyperplasia
to endometrial cancer. Plasma concentrations of GDF-15 were compared between 78 patients
with endometrial hyperplasias and 235 patients with primary endometrial cancer. There was no
significant difference between plasma levels of GDF-15 in endometrial hyperplasias (1502 ng/L;
95% CI, 1219–1785 ng/L) and primary tumors (1611 ng/L; 95% CI, 1446–1776 ng/L) (p = 0.807).
When performing a more detailed analysis of endometrioid endometrial cancers only, we
observed that the increase of GDF-15 occurs between grade 1 and grade 2 (p = 0.003, Fig 2A).
Elevated plasma level of GDF-15 is associated with recurrent disease
Given the association with aggressive disease, we investigated if GDF-15 could be a marker for
recurrence. When analyzing blood samples from endometrial cancer patients at time of
Table 1. GDF-15 measured in plasma samples from 235 patients with endometrial cancer in relation to clinico-
pathological factors.
Low, n (%) High, n (%) P-value�
Age, y <0.001
<66 86 (84) 16 (16)
�66 71 (53) 62 (47)
FIGO 0.003
I/II 140 (71) 58 (29)
III/IV 17 (46) 20 (54)
Histologic type 0.002
Endometrioid 126 (72) 48 (28)
Non-endometrioid 31 (51) 30 (49)
Non-endometrioid types 0.003
Clear cell 4 (40) 6 (60)
Serous 20 (61) 13 (39)
Carcinosarcomas 3 (25) 9 (75)
Undifferentiated 4 (67) 2 (33)
Histologic grade�� 0.002
Grade 1 76 (84) 15 (16)
Grade 2 27 (55) 22 (45)
Grade 3 18 (64) 10 (36)
Myometrial infiltration 0.001
<50% 101 (75) 33 (25)
�50% 55 (56) 44 (44)
�P-values are calculated by Chi-Square test or Fisher exact test.
��Endometrioid included only.
Low = 1. and 2. tertile
High = 3. tertile
FIGO: International Federation of Gynecology and Obstetrics
https://doi.org/10.1371/journal.pone.0210585.t001
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primary treatment, the preoperative level of plasma GDF-15 was significantly higher for patients
who later experienced recurrence (1780 ng/L; 95% CI; 518–9475 ng/L) than for patients who
did not develop recurrent disease (1236 ng/L; 95% CI; 307–7030 ng/L) (p <0.001, Fig 2B). This
might indicate a potential for GDF-15 in predicting recurrence. To investigate this further,
plasma samples were collected at time of recurrence from 36 patients, and compared to corre-
sponding plasma samples collected at time of primary treatment. For these patients, with avail-
able paired samples, plasma levels of GDF-15 at recurrence (2818 ng/L, 95% CI 2088–3548 ng/
L) were significantly higher than plasma levels of GDF-15 measured at time of primary diagno-
sis (1857 ng/L, 95% CI; 1317–2398 ng/L) (p = 0.001, Fig 2C). This may suggest a role for GDF-
15 in monitoring recurrence.
Plasma GDF-15 independently predicts lymph node metastases and
recurrence
A prediction model for recurrence was calculated from our merged cohort of 603 patients
(described in materials). The cut-off value grouping high and low GDF-15 was 1418 ng/L.
Patients with high plasma level of GDF-15 had significantly higher risk of recurrent disease
(OR = 3.14; 95% CI 2.10–4.76) in univariate analysis. In the multivariate model, after adjusting
for age, postoperative histology and depth of myometrial infiltration, the predictive value
Table 2. GDF-15 in plasma samples in relation to clinicopathological factor in patients with preoperative low-risk
staging�.
Low, n (%) High, n (%) P-value#
Age, years 0.005
<66 59 (83) 12 (17)
�66 48 (62) 19 (38)
FIGO 0.36
I/II 98 (74) 35 (26)
III/IV 9 (60) 6 (40)
Histologic type 0.218
Endometrioid 103 (74) 37 (26)
Non-endometrioid 4 (50) 4 (50)
Non-endometrioid types 0.242
Clear cell 0 1 (100)
Serous 3 (50) 3 (50)
Carcinosarcomas 1 (100) 0
Histologic grade�� 0.007
Grade 1 70 (82) 15 (18)
Grade 2 24 (57) 18 (43)
Grade 3 5 (56) 4 (44)
Myometrial infiltration 0.007
<50% 73 (80) 18 (20)
�50% 34 (60) 23 (40)
�Low-risk patients defined as endometrioid histology and grade 1 or grade 2 disease on preoperative curettage.
��Endometrioid included only.
#P-values are calculated by Chi-square test or Fisher exact test.
Low = 1. and 2. tertile
High = 3. tertile
FIGO: International Federation of Gynecology and Obstetrics
https://doi.org/10.1371/journal.pone.0210585.t002
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remained significant with an adjusted OR of 1.99 (95% CI 1.23–3.22, Table 3). Furthermore, in
the merged cohort of 495 patients with lymph node status (also described in materials and cut-
off value of 1418 ng/L), high plasma level of GDF-15 was significantly associated with lymph
node metastases (OR = 2.64; 95% CI 1.52–4.61) in univariate analysis. In multivariate analysis,
adjusting for preoperative histological risk (high; endometrioid grade 3 or non-endometrioid
versus low; endometrioid grade 1 or 2) the predictive value of GDF-15 remained significant
with an adjusted OR of 2.49 (95% CI 1.42–4.37, Table 4). Age was not significant in in
Fig 2. Box plots showing plasma level of GDF-15 in hyperplasias and grade 1–3 (A), in patients who experienced
recurrence during their follow-up and in patients who did not (B) and plasma level of GDF-15 in paired samples at
time of primary diagnosis and at time of recurrence (C). Number of cases are given. P-values are calculated by the
Mann Whitney U test in independent samples and Wilcoxon Signed Rank test in related samples. �Endometrioid
included only.
https://doi.org/10.1371/journal.pone.0210585.g002
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univariate analysis and was therefore not included in the multivariate analysis. Statistical
power was too low to perform the analysis in the independent cohort of 235 patients.
High tumor volume detected by MRI is associated with high plasma GDF-
15
In order to further validate GDF-15 as a preoperative marker of prognosis, we compared
plasma levels of GDF-15 with imaging variables from routine preoperative MRI (n = 141).
Patients with high plasma level of GDF-15 had significantly larger tumor volume; with mean
tumor size of 17 ml (95% CI: 12–22 ml) in patients with low GDF-15 as opposed to mean
tumor size of 27 ml (95% CI: 13–40 ml) in patients with high GDF-15 (p = 0.008). Also, high
plasma level of GDF-15 was associated with MRI assessed deep myometrial infiltration
(p = 0.05) and cervical stroma invasion (p = 0.03, Table 5).
Discussion
Biomarkers derived from blood samples are easily available and has been less explored com-
pared to tissue biomarkers in endometrial cancer. GDF-15 in plasma has previously been pro-
posed as a biomarker in endometrial cancer [20], and has also been suggested as a serum
biomarker in patients with prostate, pancreatic and colon cancers [13, 14, 16]. In addition,
Table 3. Prediction of recurrence in 603 patients with endometrial cancer, univariate and multivariate logistic regression.
Variable N Univariate OR 95% CI P Multivariate OR 95% CI P
Age <0.001 0.043
603 1.05 1.03–1.07 1.02 1.00–1.05
Histology <0.001 <0.001
Endometrioid 492
Non-endometrioid 111 4.50 2.86–7.09 3.72 2.29–6.05
Myometrial infiltration <0.001
<50% 390 <0.001
�50% 213 2.67 1.77–4.04 2.27 1.45–3.55
GDF-15 <0.001 0.005
Low 419
High tertile 184 3.14 2.07–4.76 1.99 1.23–3.22
Variables significant in univariate analyses were used in the final multivariate model.
https://doi.org/10.1371/journal.pone.0210585.t003
Table 4. Prediction of lymph node metastases in 495 patients with endometrial cancer, univariate and multivariate logistic regression.
Variable N Univariate OR 95% CI P Multivariate OR 95% CI P
Curretage histology 0.014 0.036
Low risk� 373
High risk�� 122 2.06 1.16–3.66 1.87 1.04–3.37
GDF-15 0.001 0.001
Low 346
High tertile 149 2.64 1.52–4.61 2.49 1.42–4.37
Variables significant in univariate analyses were used in the final multivariate model.
�Low-risk patients defined as endometrioid histology and grade 1 or grade 2 disease on preoperative curettage.
��High-risk patients defined as endometrioid histology and grade 3 disease or non-endometrioid histology on preoperative curettage.
https://doi.org/10.1371/journal.pone.0210585.t004
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GDF-15 has been proposed as a general predictor of cardiovascular disease [23] also in appar-
ently healthy women [24]. In this study, we validate that high level of plasma GDF-15 is associ-
ated with clinical characteristics depicting aggressive disease and poor survival in endometrial
cancer. In previous studies by Staff et al. elevated plasma level of GDF-15 was associated with
aggressive histologic types, lymph node metastases, reduced recurrence-free survival, and
death due to endometrial cancer [20]. Our results are in line with these findings and validate
GDF-15 as a prognostic marker in endometrial carcinoma.
Plasma biomarkers might be useful for screening if a marker could detect early stages of dis-
ease. However, we did not find that plasma levels of GDF-15 distinguish between hyperplasias
and grade 1 endometrioid endometrial cancers. Previous reports have identified an increase in
plasma GDF-15 from healthy controls to cancer [14, 16, 20]. It is interesting that hyperplasias
show similarly high plasma GDF-15 compared to grade 1 endometrioid endometrial cancers.
This may indicate that elevation of GDF-15 is an early event and occurs simultaneously with
development of hyperplasias. It has previously been reported that serum GDF-15 levels pro-
gressively increase from premalignant colonic lesions to cancer initiation with a further
increase of plasma levels GDF-15 at time of metastasis [16]. It is known that GDF-15 can
induce various pleiotropic effects during cancer progression by negatively or positively modu-
lating cell proliferation, differentiation, apoptosis, invasion, and metastases, dependent of can-
cer cell types, disease stage, and tumor microenvironment [25]. However, the function of
GDF-15 is not yet fully understood. A more thorough investigation of GDF-15 in early stages
of disease should include large cohorts of controls and hyperplasias, preferentially also with
repeated sampling of individual patients.
For endometrial cancer, there is a need to preoperatively identify patients with aggressive
disease to stratify for optimal treatment. Presently, preoperative diagnosis relies on risk classifi-
cation based on a preoperative biopsy and at some centers, preoperative imaging, preferen-
tially MRI, is included. Addition of an easily obtainable serum biomarker could add relevant
information. Importantly, we find that in patients with putative low risk based on preoperative
histology (endometrioid grade 1 or 2), high level of GDF-15 predicts poor prognosis and is
associated with aggressive features in endometrial cancer. In contrast, low-risk patients with
low levels of GDF-15 have a 5-year survival of 97%. This suggests a promising role for GDF-15
in confirming preoperatively that some putative low-risk patients have an excellent prognosis,
supporting the clinical value of plasma GDF-15 in endometrial cancer treatment.
Additionally important for treatment of endometrial cancer patients is the ability to identify
patients with risk of recurrence. We here find that in preoperative samples, plasma levels of
GDF-15 are higher for patients that later experience recurrent disease compared to patients
Table 5. Clinical characteristics on preoperative MRI in 141 patients in relation to plasma level of GDF-15.
Low n (%) High n (%) P- value�
Myometrial infiltration 0.05
<50% 63 (85) 11 (15)
�50% 48 (72) 19 (28)
Cervical stroma affection 0.03
no 90 (84) 17 (16)
yes 7 (58) 5 (42)
�P-values are calculated by Chi-Square test.
Low = 1. and 2. tertile
High = 3. tertile
https://doi.org/10.1371/journal.pone.0210585.t005
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that do not experience recurrence. Further analyses showed the same for paired samples,
where level of GDF-15 increased in samples from primary treatment to samples obtained at
time of recurrence. When adjusting for age, histology and myometrial infiltration, high plasma
level of GDF-15 was an independent marker for predicting recurrence. To the best of our
knowledge we demonstrate for the first time that elevated levels of GDF-15 may be helpful in
follow-up of patients to detect recurrence. Although the sample size of 36 paired samples is
low, the results are promising and indicating a role for GDF-15 in monitoring recurrence. The
increase of GDF-15 in aggressive disease and recurrence has been reported in gene- expression
signatures from circulating tumor cells [26], further emphasizing our findings. Measuring
GDF-15 in plasma from patients with endometrial cancer may be helpful when selecting
women who are likely to profit from adjuvant therapy after primary treatment. Monitoring
plasma levels of GDF-15 during follow-up can potentially also guide the recommended fre-
quency of follow-up examinations including diagnostic imaging such as MRI or Computer
Tomography (CT) after primary treatment.
Interestingly, GDF-15 was superior to histological risk classification in predicting meta-
static lymph nodes. GDF-15 could therefore be helpful as an indicator of lymph node metasta-
ses and when selecting women for lymphadenectomy. The value of lymph node sampling is
controversial and studies are not convincing when evaluating survival benefit and short- and
long term complications for the patients who undergo lymphadenectomy [27]. Thus, markers
for better prediction of lymph node metastasis may be valuable in the clinic. Novel techniques,
such as sentinel lymph node mapping in endometrial carcinoma is increasingly acknowledged
[28], however it has limitations among others in relation to obese patients and is still not
implemented in most countries, thus a marker in blood samples is still clinically relevant.
Using imaging methods as an adjunct to preoperative serum or tumor biopsy risk stratifica-
tion may be a useful clinical tool. We demonstrated correlation between plasma GDF-15 and
MRI determined tumor size and cervical infiltration. MRI has been reported to outperform
that of endocervical curettage for preoperative prediction of cervical stromal invasion [29].
Also, for differentiation of low grade endometrial cancer from endometrial hyperplasia, preop-
erative MRI and FDG-PET yield promising imaging markers [30]. Imaging markers may thus
be better than plasma GDF-15 in detecting early disease since the elevation of GDF-15 seems
to occur prior to cancer development. However, the patient population with available imaging
data should be larger to validate these findings.
Endometrial cancer is associated with both obesity and high age, factors known to increase
the risk of comorbidity such as cardiovascular disease. Cardiovascular disease is not systemati-
cally reported in our cohort, and could potentially have biased our results due to its association
with high plasma GDF-15 [23, 24]. However, the use of disease-specific survival in our survival
analyses and the identified association with both high grade and myometrial infiltration,
which is independent of comorbidity and high age, support that GDF-15 specifically detects
aggressive endometrial cancer in our cohort. Also, given the association that high plasma level
of GDF-15 decreases time to recurrence, further emphasizes that GDF-15 is increased due to
the patient’s cancer status as reduced time to recurrence is not likely to be influenced by car-
diovascular disease.
Few biomarkers have so far been identified from plasma [2–4] and blood derived markers
would be useful in clinical practice as they are less invasive for the patient, are relatively inex-
pensive and may prove helpful both for preoperative prognostication and in detecting recur-
rent disease during follow-up. Monitoring plasma levels of GDF-15 during follow-up can
potentially guide clinicians when to refer patients to renewed diagnostic imaging by MRI and
Computer Tomography (CT) or FDG PET-CT to detect recurrence. Robust plasma markers
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could thus represent a valuable tool in clinical practice. However, further and larger studies are
needed to further evaluate GDF-15 as a plasma marker for recurrence.
We conclude that elevated levels of plasma GDF-15 is associated with an aggressive clinical
phenotype and lymph node metastasis in endometrial carcinomas. Elevated GDF-15 is also a
marker of recurrent disease at time of recurrence. The clinical value of plasma GDF-15 for pre-
diction of lymph node metastases, prognostication and as a marker of recurrent disease, how-
ever, needs to be validated in larger patient cohorts and in clinical trials prior to potential
implementation in the clinic.
Acknowledgments
We thank Ellen Valen, Ann Helen Pridesis, Britt Edvardsen and Kadri Madissoo for technical
assistance.
Author Contributions
Conceptualization: Jone Trovik, Camilla Krakstad.
Data curation: Hilde Engerud, Camilla Krakstad.
Formal analysis: Hilde Engerud, Jone Trovik, Camilla Krakstad.
Funding acquisition: Jone Trovik, Camilla Krakstad.
Investigation: Hilde Engerud, Hege Fredriksen Berg, Ingfrid Salvesen Haldorsen, Jone Trovik,
Camilla Krakstad.
Methodology: Hilde Engerud, Kirsten Hope, Hege Fredriksen Berg, Ingfrid Salvesen Haldor-
sen, Jone Trovik, Camilla Krakstad.
Project administration: Jone Trovik, Camilla Krakstad.
Resources: Kristine Eldevik Fasmer, Ingfrid Salvesen Haldorsen, Jone Trovik, Camilla
Krakstad.
Supervision: Ingvild Løberg Tangen, Ingfrid Salvesen Haldorsen, Jone Trovik, Camilla
Krakstad.
Writing – original draft: Hilde Engerud, Jone Trovik, Camilla Krakstad.
Writing – review & editing: Kirsten Hope, Hege Fredriksen Berg, Kristine Eldevik Fasmer,
Ingvild Løberg Tangen, Ingfrid Salvesen Haldorsen, Jone Trovik, Camilla Krakstad.
References
1. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lan-
cet. 2005; 366(9484):491–505. Epub 2005/08/09. https://doi.org/10.1016/S0140-6736(05)67063-8
PMID: 16084259.
2. Tangen IL, Kopperud RK, Visser NC, Staff AC, Tingulstad S, Marcickiewicz J, et al. Expression of
L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metasta-
ses and poor outcome in endometrial cancer patients. Br J Cancer. 2017; 117(6):840–7. Epub 2017/07/
29. https://doi.org/10.1038/bjc.2017.235 PMID: 28751757; PubMed Central PMCID:
PMCPMC5589986.
3. Knific T, Vouk K, Smrkolj S, Prehn C, Adamski J, Rizner TL. Models including plasma levels of sphingo-
myelins and phosphatidylcholines as diagnostic and prognostic biomarkers of endometrial cancer. J
Steroid Biochem Mol Biol. 2018; 178:312–21. Epub 2018/01/24. https://doi.org/10.1016/j.jsbmb.2018.
01.012 PMID: 29360580.
4. Baydar T, Yuksel O, Sahin TT, Dikmen K, Girgin G, Sipahi H, et al. Neopterin as a prognostic biomarker
in intensive care unit patients. J Crit Care. 2009; 24(3):318–21. Epub 2009/03/31. https://doi.org/10.
1016/j.jcrc.2008.06.013 PMID: 19327301.
GDF-15 predicts aggressive disease in endometrial cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0210585 January 15, 2019 11 / 13
5. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, et al. MIC-1, a novel macro-
phage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S
A. 1997; 94(21):11514–9. Epub 1997/10/23. PMID: 9326641; PubMed Central PMCID:
PMCPMC23523.
6. Zimmers TA, Jin X, Hsiao EC, McGrath SA, Esquela AF, Koniaris LG. Growth differentiation factor-15/
macrophage inhibitory cytokine-1 induction after kidney and lung injury. Shock. 2005; 23(6):543–8.
Epub 2005/05/18. PMID: 15897808.
7. Bauskin AR, Brown DA, Kuffner T, Johnen H, Luo XW, Hunter M, et al. Role of macrophage inhibitory
cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res. 2006; 66(10):4983–6. Epub 2006/05/
19. https://doi.org/10.1158/0008-5472.CAN-05-4067 PMID: 16707416.
8. Wollert KC, Kempf T, Peter T, Olofsson S, James S, Johnston N, et al. Prognostic value of growth-dif-
ferentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation. 2007;
115(8):962–71. Epub 2007/02/07. https://doi.org/10.1161/CIRCULATIONAHA.106.650846 PMID:
17283261.
9. Kempf T, Bjorklund E, Olofsson S, Lindahl B, Allhoff T, Peter T, et al. Growth-differentiation factor-15
improves risk stratification in ST-segment elevation myocardial infarction. Eur Heart J. 2007; 28
(23):2858–65. Epub 2007/11/06. https://doi.org/10.1093/eurheartj/ehm465 PMID: 17977844.
10. Lawton LN, Bonaldo MF, Jelenc PC, Qiu L, Baumes SA, Marcelino RA, et al. Identification of a novel
member of the TGF-beta superfamily highly expressed in human placenta. Gene. 1997; 203(1):17–26.
Epub 1998/01/13. PMID: 9426002.
11. Tong S, Marjono B, Brown DA, Mulvey S, Breit SN, Manuelpillai U, et al. Serum concentrations of mac-
rophage inhibitory cytokine 1 (MIC 1) as a predictor of miscarriage. Lancet. 2004; 363(9403):129–30.
Epub 2004/01/17. https://doi.org/10.1016/S0140-6736(03)15265-8 PMID: 14726168.
12. Sugulle M, Dechend R, Herse F, Weedon-Fekjaer MS, Johnsen GM, Brosnihan KB, et al. Circulating
and placental growth-differentiation factor 15 in preeclampsia and in pregnancy complicated by diabe-
tes mellitus. Hypertension. 2009; 54(1):106–12. Epub 2009/05/28. https://doi.org/10.1161/
HYPERTENSIONAHA.109.130583 PMID: 19470878; PubMed Central PMCID: PMCPMC4167791.
13. Brown DA, Stephan C, Ward RL, Law M, Hunter M, Bauskin AR, et al. Measurement of serum levels of
macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer
diagnosis. Clin Cancer Res. 2006; 12(1):89–96. Epub 2006/01/07. https://doi.org/10.1158/1078-0432.
CCR-05-1331 PMID: 16397029.
14. Koopmann J, Buckhaults P, Brown DA, Zahurak ML, Sato N, Fukushima N, et al. Serum macrophage
inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res. 2004;
10(7):2386–92. Epub 2004/04/10. PMID: 15073115.
15. de Wit NJ, Rijntjes J, Diepstra JH, van Kuppevelt TH, Weidle UH, Ruiter DJ, et al. Analysis of differential
gene expression in human melanocytic tumour lesions by custom made oligonucleotide arrays. Br J
Cancer. 2005; 92(12):2249–61. Epub 2005/05/19. https://doi.org/10.1038/sj.bjc.6602612 PMID:
15900300; PubMed Central PMCID: PMCPMC2361822.
16. Brown DA, Ward RL, Buckhaults P, Liu T, Romans KE, Hawkins NJ, et al. MIC-1 serum level and geno-
type: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res. 2003; 9
(7):2642–50. Epub 2003/07/12. PMID: 12855642.
17. Johnen H, Lin S, Kuffner T, Brown DA, Tsai VW, Bauskin AR, et al. Tumor-induced anorexia and weight
loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat Med. 2007; 13(11):1333–40. Epub
2007/11/06. https://doi.org/10.1038/nm1677 PMID: 17982462.
18. Staff AC, Bock AJ, Becker C, Kempf T, Wollert KC, Davidson B. Growth differentiation factor-15 as a
prognostic biomarker in ovarian cancer. Gynecol Oncol. 2010; 118(3):237–43. Epub 2010/06/26.
https://doi.org/10.1016/j.ygyno.2010.05.032 PMID: 20576287.
19. Trovik J, Salvesen HB, Cuppens T, Amant F, Staff AC. Growth differentiation factor-15 as biomarker in
uterine sarcomas. Int J Gynecol Cancer. 2014; 24(2):252–9. Epub 2014/01/10. https://doi.org/10.1097/
IGC.0000000000000037 PMID: 24401984.
20. Staff AC, Trovik J, Eriksson AG, Wik E, Wollert KC, Kempf T, et al. Elevated plasma growth differentia-
tion factor-15 correlates with lymph node metastases and poor survival in endometrial cancer. Clin Can-
cer Res. 2011; 17(14):4825–33. Epub 2011/05/28. https://doi.org/10.1158/1078-0432.CCR-11-0715
PMID: 21616994.
21. Kempf T, Horn-Wichmann R, Brabant G, Peter T, Allhoff T, Klein G, et al. Circulating concentrations of
growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart
failure as assessed by a new immunoradiometric sandwich assay. Clin Chem. 2007; 53(2):284–91.
Epub 2006/12/23. https://doi.org/10.1373/clinchem.2006.076828 PMID: 17185363.
22. Haldorsen IS, Gruner R, Husby JA, Magnussen IJ, Werner HM, Salvesen OO, et al. Dynamic contrast-
enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence. Eur Radiol.
GDF-15 predicts aggressive disease in endometrial cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0210585 January 15, 2019 12 / 13
2013; 23(10):2916–25. Epub 2013/06/05. https://doi.org/10.1007/s00330-013-2901-3 PMID:
23732687.
23. Wiklund FE, Bennet AM, Magnusson PK, Eriksson UK, Lindmark F, Wu L, et al. Macrophage inhibitory
cytokine-1 (MIC-1/GDF15): a new marker of all-cause mortality. Aging Cell. 2010; 9(6):1057–64. Epub
2010/09/22. https://doi.org/10.1111/j.1474-9726.2010.00629.x PMID: 20854422; PubMed Central
PMCID: PMCPMC4139960.
24. Brown DA, Breit SN, Buring J, Fairlie WD, Bauskin AR, Liu T, et al. Concentration in plasma of macro-
phage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study.
Lancet. 2002; 359(9324):2159–63. Epub 2002/07/02. https://doi.org/10.1016/S0140-6736(02)09093-1
PMID: 12090982.
25. Mimeault M, Batra SK. Divergent molecular mechanisms underlying the pleiotropic functions of macro-
phage inhibitory cytokine-1 in cancer. J Cell Physiol. 2010; 224(3):626–35. Epub 2010/06/26. https://
doi.org/10.1002/jcp.22196 PMID: 20578239; PubMed Central PMCID: PMCPMC2932466.
26. Alonso-Alconada L, Muinelo-Romay L, Madissoo K, Diaz-Lopez A, Krakstad C, Trovik J, et al. Molecu-
lar profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. Mol
Cancer. 2014; 13:223. Epub 2014/09/30. https://doi.org/10.1186/1476-4598-13-223 PMID: 25261936;
PubMed Central PMCID: PMCPMC4190574.
27. group As, Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lympha-
denectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009; 373
(9658):125–36. Epub 2008/12/17. https://doi.org/10.1016/S0140-6736(08)61766-3 PMID: 19070889;
PubMed Central PMCID: PMCPMC2646126.
28. Tanner E, Puechl A, Levinson K, Havrilesky LJ, Sinno A, Secord AA, et al. Use of a novel sentinel
lymph node mapping algorithm reduces the need for pelvic lymphadenectomy in low-grade endometrial
cancer. Gynecol Oncol. 2017; 147(3):535–40. Epub 2017/10/24. https://doi.org/10.1016/j.ygyno.2017.
10.020 PMID: 29056441.
29. Haldorsen IS, Berg A, Werner HM, Magnussen IJ, Helland H, Salvesen OO, et al. Magnetic resonance
imaging performs better than endocervical curettage for preoperative prediction of cervical stromal inva-
sion in endometrial carcinomas. Gynecol Oncol. 2012; 126(3):413–8. Epub 2012/05/23. https://doi.org/
10.1016/j.ygyno.2012.05.009 PMID: 22609110.
30. Berg A, Gulati A, Ytre-Hauge S, Fasmer KE, Mauland KK, Hoivik EA, et al. Preoperative imaging mark-
ers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and
low grade cancers. Oncotarget. 2017; 8(40):68530–41. Epub 2017/10/06. https://doi.org/10.18632/
oncotarget.19708 PMID: 28978135; PubMed Central PMCID: PMCPMC5620275.
GDF-15 predicts aggressive disease in endometrial cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0210585 January 15, 2019 13 / 13
Graphic design: Com
m
unication Division, UiB  /  Print: Skipnes Kom
m
unikasjon AS
uib.no
ISBN: 9788230850138 (print)
9788230868195 (PDF)
